双氢青蒿素哌喹(Piperaquine tetraphosphate/Artenimol) - 药物靶点：CYP3A4_在研适应症：恶性疟_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Artekin、DHA - PPQ、DHA/PPQ

+ [11]

靶点

CYP3A4

作用方式

抑制剂

作用机制

CYP3A4抑制剂(细胞色素P450家族成员3A4抑制剂)

治疗领域

感染

在研适应症

恶性疟

非在研适应症

间日疟原虫感染

原研机构

Holleykin Pharma Ltd.

在研机构

Alfasigma SpA

贝克诺顿（浙江）制药有限公司

非在研机构

Sigma-Tau Industrie Farmaceutiche Riunite SpA

权益机构-

最高研发阶段批准上市

首次获批日期

中国 (2004-12-07),

恶性疟

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

关联

153

项与双氢青蒿素哌喹相关的临床试验

PACTR202607738028407

/ SuspendedN/AIIT

Open label randomized study to evaluate the in vivo efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in children 6 months to 10 years of age in western Kenya

开始日期2026-12-01

申办/合作机构

Program for Appropriate Technology in Health

PACTR202607921693996

/ Suspended临床2期IIT

A Phase IIb open-label randomized trial to assess the immunogenicity and safety of the malaria vaccine R21/Matrix-M™ combined with post-discharge malaria chemoprevention (PDMC) with dihydroartemisinin-piperaquine (DHA-PPQ) in children 6-60 months of age at high risk for re-admission and death in Ghana.

开始日期2026-12-01

申办/合作机构-

NCT07021430

/ Recruiting早期临床1期IIT

Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy: a Pilot Randomized Controlled Trial

The purpose of this study is to demonstrate the feasibility, acceptability, and preliminary effectiveness of a focal mass drug administration program for household members of pregnant women to protect against malaria in pregnancy.

开始日期2026-09-27

申办/合作机构

The University of North Carolina at Chapel Hill

[+1]

100 项与双氢青蒿素哌喹相关的临床结果

登录后查看更多信息

100 项与双氢青蒿素哌喹相关的转化医学

登录后查看更多信息

100 项与双氢青蒿素哌喹相关的专利（医药）

登录后查看更多信息

156

项与双氢青蒿素哌喹相关的文献（医药）

2026-07-01·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of malaria intermittent preventive treatment with dihydroartemisinin-piperaquine on antiretroviral drug concentrations in African pregnant women living with HIV

Article

作者: Gamberini, Sara ; Figueroa-Romero, Antía ; Mischlinger, Johannes ; Saúte, Francisco ; Lell, Bertrand ; Tchouatieu, André-Marie ; Stöger, Linda ; Ndzebe Ndoumba, Wilfrid ; Mendes, Anete ; Méndez, Susana ; Zoleko-Manego, Rella ; Wicha, Sebastian G. ; Sevene, Esperança ; Dimessa Mbadinga, Lia Betty ; Piqueras, Mireia ; González, Raquel ; Soy, Dolors ; Nhampossa, Tacilta ; Menéndez, Clara ; Ramharter, Michael ; Sanz, Sergi ; Lagler, Heimo ; El Gaaloul, Myriam ; Brunet, Mercè ; Botella, Núria ; Mombo-Ngoma, Ghyslain ; Esen, Meral

ABSTRACT:

Intermittent preventive treatment during pregnancy (IPTp) for malaria prevention with sulfadoxine-pyrimethamine is contraindicated in pregnant women living with HIV receiving cotrimoxazole prophylaxis. A recent clinical trial showed that dihydroartemisinin-piperaquine (DHA-PPQ) for IPTp is a safe and effective option for malaria prevention in this population. The present study evaluated the impact of monthly IPTp with DHA-PPQ on antiretroviral (ARV) drug concentrations in 105 participants recruited in the aforementioned trial in Mozambique and Gabon between January and November 2021. ARV serum concentrations from maternal venous and cord blood collected at the first antenatal care visit and at the end of pregnancy were measured by ultra-high-performance liquid chromatography-tandem mass spectrometry. At the end of pregnancy, median concentrations of dolutegravir were 835.1 ng/mL (248.1–1,687.6) in maternal and 1,204.2 ng/mL (456.4–1,883.3) in cord blood. For lamivudine (3TC), median concentrations were 108.3 ng/mL (28.8–246.1) in maternal and 186.5 ng/mL (81.9–427.6) in cord blood. No significant differences in ARV concentrations were found between the antimalarial treatment arm and the placebo arm. Furthermore, in multivariate exploratory analysis, no independent associations were found between ARV concentrations and participant characteristics. Our study found similar ARV concentrations in both treatment groups, suggesting that DHA-PPQ for monthly IPTp does not affect ARV concentrations in maternal and cord blood in women living with HIV.

CLINICAL TRIALS:

This study is registered with ClinicalTrials.gov as NCT03671109 .

2026-05-01·LANCET INFECTIOUS DISEASES

Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, single-centre, randomised clinical trial

Article

作者: Rocha, Yasmin Vieira ; da Silva Balieiro, Antônio AlcirleyC ; Barreiros, Gilce Alves ; Baía-da-Silva, Djane C ; Bassat, Quique ; Jerônimo, Christiane Maria Prado ; Filho, Aristóteles Comte Alencar ; Machado, Kim Vinícius AmaralC ; Nascimento, Cristiana T ; Alencar, Aline C C ; Carrilho, Thaís Alves Amaral ; Vieira, José Luiz Fernandes ; Lacerda, Marcus V G ; Costa, Mônica Regina FariasC ; Valle, Cristiane Siqueira ; Marcovski, Mariana Souza ; Omena, Aretha Gomes ; Barbosa, Laila Rowena Albuquerque ; Melo, Gisely C ; Brito-Sousa, José Diego ; Sampaio, Vanderson S ; Alecrim, Maria das Graças C ; Dinelly, Kelry Mazurega Oliveira ; Rabelo, Amanda Lia RebêloC ; Alexandre, Marcia A A ; Barbosa, Antônio S Lc ; Siqueira, André M ; de Melo, Marly Marques

BACKGROUND:

We aimed to evaluate the efficacy and tolerability of dihydroartemisinin-piperaquine as an alternative schizontocide to chloroquine for the treatment of Plasmodium vivax malaria in Brazil, where early recurrences despite chloroquine therapy and operational challenges with primaquine adherence highlight the need to assess alternative treatment regimens.

METHODS:

Curavivax was an open-label, single-centre, parallel-group, randomised trial done in a public reference centre for infectious diseases in Manaus (Brazilian Amazon). Patients older than 6 months with microscopically confirmed P vivax malaria, weighing up to 100 kg, with glucose-6-phosphate dehydrogenase activity greater than 30% of normal, were randomly assigned (1:1:1:1), based on a computer-generated list of blocks of five participants, to dihydroartemisinin-piperaquine or chloroquine plus primaquine initiated on day 0 or delayed until day 42. Dihydroartemisinin-piperaquine (40/320 mg or 20/160 mg oral tablets) and chloroquine (150 mg oral tablets) were administered once daily for 3 days. Primaquine (15 mg oral tablets) was administered once daily for 14 days. All medicines were dosed by bodyweight and dispensed open-label. The primary outcome was the recurrence rate at day 42 in the per-protocol population. Safety was assessed in all participants who received at least one dose of study medication. This trial was registered with ClinicalTrials.gov, NCT03208907, and is completed.

FINDINGS:

Between July 5, 2018, and Jan 13, 2021, 1649 patients were screened for eligibility, 419 of whom were randomly assigned to chloroquine plus primaquine (n=114), dihydroartemisinin-piperaquine plus primaquine (n=112), chloroquine plus delayed primaquine (n=98), and dihydroartemisinin-piperaquine plus delayed primaquine (n=95). One patient in the chloroquine plus primaquine group was excluded owing to a severe protocol deviation. 287 (69%) of 418 patients were male and 131 (31%) were female. Day 42 recurrence rate in the per-protocol population was similar for chloroquine plus primaquine (2·0% [95% CI 0·2-7·0]) and dihydroartemisinin-piperaquine plus primaquine (1·0% [0·0-5·3]; hazard ratio [HR] 0·48 [95% CI 0·00-40 209·06; p=0·44); whereas dihydroartemisinin-piperaquine alone (delayed primaquine; 2·4% [0·3-8·5]) was superiorto chloroquine alone (delayed primaquine; 27·3% [18·3-37·8]; HR 0·08 [95% CI 0·00-0·22]; p<0·0001). All treatments were well tolerated.

INTERPRETATION:

The high therapeutic efficacy and early recurrence prevention with dihydroartemisinin-piperaquine with primaquine started on day 0 or delayed to day 42 supports the use of this schizontocide for P vivax treatment in Latin America.

FUNDING:

Ministry of Health of Brazil and the National Council for Scientific and Technological Development.

2026-01-07·AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Treatment Efficacy of Dihydroartemisinin–Piperaquine for Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Timika, Papua, Indonesia

Article

作者: Poespoprodjo, Jeanne Rini ; Indrawanti, Ratni ; Noviyanti, Rintis ; Hafidz, Firdaus ; Ramli, Muhammad Syawal Satria ; Kenangalem, Enny ; Trianty, Leily ; Simatupang, Minerva ; Ubra, Reynold R. ; Puspitasari, Agatha Mia ; Hill, Jenny ; Prayoga, Pak ; Candrawati, Freis ; Kambuaya, Noy Norman

ABSTRACT.:

Dihydroartemisinin–piperaquine (DP), the first-line treatment for uncomplicated malaria in Timika, Papua, Indonesia, has also been used for intermittent preventive treatment in pregnancy (IPTp-DP) since February 2022. Concerns about the potential emergence of drug resistance associated with this dual policy prompted the present study, which was conducted to assess DP efficacy in treating uncomplicated Plasmodium falciparum ( P. falciparum ) and Plasmodium vivax ( P. vivax ) malaria in the general population 15 months after IPTp-DP was introduced. Between May and December 2023, the current study recruited 75 P. falciparum and 75 P. vivax malaria patients, who received supervised DP treatment for 3 days. Clinical and laboratory data were collected daily (on days 1, 2, 3, and 7) and then weekly for 6 weeks. Molecular analysis was performed to detect genetic markers of P. falciparum resistance to DP and distinguish between recrudescence and reinfection. A total of 68 P. falciparum and 58 P. vivax patients completed their day 42 follow-up. The cumulative risk of same-species recurrence by day 42 was 1.5% (95% CI: 0–7.9%) in P. falciparum patients (polymerase chain reaction-adjusted) and 5.2% (95% CI: 1.1–14.1%) for P. vivax patients (unadjusted). No patients exhibited parasitemia on day 3. No P. falciparum isolates carried kelch 13 gene mutations or exhibited increased plasmepsin 2–3 copy numbers on either day 0 (0/75) or at recurrence (0/2). At the current level of IPTp-DP coverage (824 doses administered), there was no evidence of high treatment failure rates or the selection of resistant parasites in patients with uncomplicated malaria treated with DP. Continuous monitoring of DP efficacy remains crucial for both treatment and chemoprevention.

24

项与双氢青蒿素哌喹相关的新闻（医药）

2026-08-21

·我药说说

「药说药企」昆药集团：三七赛道的「老黄金」，正在经历一场央企改造的阵痛

——「药说药企」深度解读第 001 期目录 1. 一句话速览：这家公司，到底行不行 2. 公司的"底片"：从昆明制药厂到华润系一员 3. 它靠什么赚钱：一条"三七"主线，串起半个世纪的生意 4. 王牌产品深拆：血塞通——一款药如何撑起一家上市公司 5. 研发管线：低调的"天然植物药"牌面，还藏着什么 6. 战略与资本动作：华润三九入主的"三年融合" 7. 财务体检：2024年的"历史新高"与2025年的"断崖" 8. 行业位置与竞争格局：三七赛道的"唯一玩家" 9. 风险与隐忧：集采、单品依赖与转型阵痛 10. 独立判断与总结：它还是不是一只"黄金股" 11. 参考文献与数据来源 1. 一句话速览：这家公司，到底行不行如果要在 A 股找一家"几乎没人系统写过、却背负着半个世纪中国现代制药史"的公司，昆药集团（600422.SH）绝对排得上号。它有几个反差强烈的标签： - 它很老：前身是 1951 年成立的昆明制药厂，比绝大多数读者年纪都大。 - 它很"红"：是青蒿素（抗疟药，屠呦呦因此获诺贝尔奖）产业链上的重要产业化企业之一。 - 它很"独"：手握血塞通（三七总皂苷制剂）这一单品，在软胶囊剂型上，全国市场一度只有它和同门兄弟华润圣火两家生产。 - 它很"央企"：2023 年起控股股东变为央企华润旗下的华润三九，正在经历一场"三年融合"的深度改造。但这样一家"老黄金"，当下的财报却相当难看： 2025 年，昆药集团营收 65.75 亿元，同比下滑 21.74%；归母净利润 3.50 亿元，同比下滑 46.00%；扣非净利润 1.07 亿元，同比下滑 74.45%。（来源：昆药集团 2025 年年度报告，2026-03-19 披露）更关键的是，公司在 2026 年 7 月 14 日发布的半年度业绩预告显示，预计 2026 年上半年归母净利润亏损 3.3 亿～4 亿元。（来源：昆药集团 2026 年半年度业绩预告公告）一家曾经净利润创历史新高的公司，为什么会在一年之内掉头向下？它到底是"被市场错杀的黄金"，还是"正在褪色的老品牌"？这正是这篇文章要完整、客观还原的。（说明：本文所有财务数据、股权结构、产品信息均来自昆药集团公开披露的年报、公告及权威媒体/券商研报，文末附完整来源；文章仅作信息整理与学习交流，不构成任何投资建议。） 2. 公司的"底片"：从昆明制药厂到华润系一员 2.1 出身：云南高原上的一家中药厂昆药集团的前身，是 1951 年 3 月成立的昆明制药厂。2000 年 12 月，公司在上海证券交易所上市，股票简称一度叫"昆明制药"，后来才更名为"昆药集团"。（来源：昆药集团 2024 年年度报告"公司简介"）云南是全国知名的"植物王国"，依托当地丰富的天然植物资源，昆药集团先后开发了青蒿、三七、天麻三大系列，以及特色中药、民族药等 40 多个天然药物新产品，形成了"以自主天然植物药为主"的业务格局。（来源：昆药集团 2024 年年度报告）独立视角：昆药集团的基因里刻着两个字——"植物药"。它不是靠一两个化合物的化药厂，而是一家把云南的草木变成药的企业。这个基因，决定了它后来的护城河，也埋下了它"单品依赖"的伏笔。 2.2 关键转折：华润三九的"A吃A"入主昆药集团近十年最重要的一件事，不是某款新药，而是一场股权层面的"改朝换代"。 - 2022 年 5 月：华润三九（000999.SZ）计划作价 29.02 亿元，收购昆药集团 28% 股份，这是一起典型的"A 吃 A"交易。 - 2022 年 12 月末：昆药集团 28% 股份过户至华润三九名下。 - 2023 年 1 月：昆药集团完成董事会、监事会改组，控股股东由华立医药变更为华润三九。实际控制人随之变更为央企中国华润有限公司。（来源：长江商报《昆药集团净利6.48亿创新高并表华润圣火存货周转率提升》，2025-03-13）独立视角：华润入主，本质上是把一家"地方的、老派的、植物药基因"的公司，纳入央企的"品牌 + 渠道 + 治理"体系。这是理解昆药集团未来所有动作的钥匙——它的战略、它的改革、它的阵痛，全都围绕"融入华润"展开。 2.3 定位重构：从"中药厂"到"银发健康引领者" 华润三九入主后，昆药集团的定位发生了根本性转变。从 2023 年起，公司年报明确聚焦"健康老龄化"赛道，锚定成为"银发健康产业引领者"的核心战略目标。公司的具体打法，浓缩为两句口号式的战略表述： - "传承精品国药"——守住中药老字号的牌面； - "做强三七产业链"——把核心资源向三七（血塞通的原料）集中。（来源：昆药集团 2024 年年度报告"经营情况讨论与分析"）独立视角：这个定位很聪明——中国正在快速老龄化，银发健康是确定性最强的长坡厚雪赛道。但"聪明"不代表"轻松"，因为从一家"卖三七药的厂"，升级成"服务老龄人口健康管理的平台"，中间隔着的不只是产品，还有组织能力、品牌认知和渠道体系的重建。这正是后文"阵痛"的根源。 3. 它靠什么赚钱：一条"三七"主线，串起半个世纪的生意 3.1 业务全景：覆盖医药全产业链昆药集团的业务覆盖医药全产业链，核心业务包括：药物研发、生产及销售、医药流通、大健康产业。（来源：昆药集团 2024 年年度报告）但从收入结构看，真正撑起公司营收的，是几条清晰的产品线（来源：昆药集团 2025 年年度报告）： 3.2 核心产品线拆解昆药集团的核心产品，主要可以分成几大系列（来源：昆药集团 2024 年年度报告、2025 年年度报告）：产品系列代表产品治疗领域市场地位血塞通系列昆药络泰血塞通系列心脑血管/慢病三七总皂苷龙头蒿甲醚系列蒿甲醚（青蒿素衍生物）抗疟出口型，WHO 采购华润圣火理洫王血塞通软胶囊心脑血管/慢病软胶囊剂型独二家昆中药系列参苓健脾胃颗粒、舒肝颗粒、香砂平胃颗粒消化/脾胃精品国药贝克诺顿阿尔治玻璃酸钠注射液骨关节炎特色制剂天麻素天麻素注射液神经/眩晕特色品种独立视角：把这张表看懂，就抓住了昆药集团的命脉——它几乎是一家"三七 + 血塞通"的公司。三七总皂苷（血塞通的活性成分）贯穿了心脑血管、慢病管理这两条最粗的主线，而青蒿素（蒿甲醚）是它的"历史功勋章"（扛疟大药），天麻、昆中药是它的"长尾补充"。 3.3 三七产业链：公司的"基本盘" 三七，是云南道地药材，素有"金不换"之称，是血塞通、复方丹参滴丸等一系列心脑血管中成药的核心原料。昆药集团是业内公认的三七产业的"头部玩家"之一。公司围绕三七产业链做的，不只是做成药，而是覆盖了种植、提取、制剂、品牌的纵向整合。（来源：昆药集团年报及公开报道）独立视角：理解昆药集团，"三七产业链"是比"某款药"更重要的概念。因为三七是它的原料壁垒（道地药材 + 提取工艺 + 品牌），也是它被华润看中的核心资产逻辑——华润要的，不只是一家药厂，而是"三七"这个在老龄健康里具有战略价值的植物药资源。 4. 王牌产品深拆：血塞通——一款药如何撑起一家上市公司 4.1 血塞通是什么血塞通（主要成分为三七总皂苷）是用于缺血性心脑血管疾病的中成药，制剂形态包括注射用血塞通（冻干粉针）和血塞通软胶囊等。它是昆药集团当之无愧的"现金牛"和"门面担当"。公司披露，注射用血塞通（冻干）、血塞通软胶囊等品种，在同品类市场份额处于领先地位。（来源：昆药集团 2024 年年度报告） 4.2 血塞通的"独二家"格局血塞通软胶囊这个剂型，全国市场曾长期只有昆药集团和华润圣火两家生产。（来源：长江商报，2025-03-13）正是因为这个"独二家"的同业竞争问题，昆药集团在华润三九的主导下，启动了收购：昆药集团以自有或自筹资金 17.91 亿元，收购华润三九持有的华润圣火 51% 股权。2024 年 12 月 20 日完成工商变更，华润圣火纳入合并报表，血塞通软胶囊的同业竞争问题得以解决。（来源：长江商报、昆药集团 2024 年年报）独立视角：这一步棋很关键——它把"三七总皂苷软胶囊"这个剂型的两家生产商，统一到了昆药集团一个盘子下，相当于在血塞通软胶囊这一细分剂型上形成了事实垄断。这是昆药集团护城河最硬的一块，也是它敢于聚焦三七、聚焦慢病的底气。 4.3 血塞通的"冰火两重天" 但成也血塞通、痛也血塞通。2025 年，血塞通系列遭遇了明显的渠道和政策冲击： - 注射用血塞通（冻干）：受医保支付政策影响，2024 年生产量、销售量同比分别下滑 60.78%、54.66%（来源：国泰海通证券研报，2025-04-20）。 - 血塞通软胶囊：2025 年生产量、销售量同比下降，主要是"多地加强对药店统筹支付药品的处方管控及慢病病种限制"影响（来源：读创财经/深圳商报《昆药集团内外夹击的2025》，2026-03-19）。独立视角：血塞通的困境，本质上是中成药集采 + 医保控费对"药店统筹支付"模式的挤压。昆药集团过去大量依赖零售终端的慢病用药走量，当政策收紧处方管控、限制慢病病种，血塞通的零售逻辑就被动摇了。这提醒我们："独二家"的护城河是剂型和准入，而不是需求本身——需求被政策卡住时，护城河也帮不了你。 5. 研发管线：低调的"天然植物药"牌面，还藏着什么昆药集团是一家以"天然植物药"为主的公司，它的研发投入体量并不算大。数据显示： - 2024 年，公司研发投入金额约 1.43 亿元，同比增 14.33%，研发投入占营收比例仅约 1.7%，研发投入资本化率 25.4%。（来源：中国证券报·中证网《昆药集团：2024年净利润同比增长19.86%》，2025-03-11）独立视角：1.7% 的研发强度，放在创新药圈子里是偏低的。但要用对逻辑看昆药集团——它不是靠"砸钱做新靶点"的创新药公司，而是靠"老品种 + 品牌 + 渠道 + 三七资源"的消费型/资源型药企。它的"研发"更多体现在：老品种的二次开发、三七提取工艺升级、经典名方/精品国药的传承创新。在研管线方面，昆药集团的低调恰恰是它的特点——它很少用"管线里程碑"来制造股价催化剂，而是把资源倾向"血塞通适应症拓展""三七产业链标准化""昆中药经典名方"等方向。（来源：昆药集团年报及公开报道，此为笔者基于公开信息的归纳）需要说明的是：昆药集团的研发管线透明度相对较低，公开披露的"创新药级别"管线信息有限。这也是一家"资源型+品牌型"药企与"biotech 型"药企的本质差异——它的未来不靠'下一个分子'，而靠'把三七这个故事讲得更大、把老龄化人群服务得更深'。 6. 战略与资本动作：华润三九入主的"三年融合" 6.1 "三年融合"与"乐成改革" 华润三九入主后，昆药集团进入一个明确的改革周期。公司在 2024 年年报中用了大量笔墨描述这场改革，关键词包括： - "三年融合"承前启后的关键之年； - "乐成改革"攻坚克难的承压之年； - "十年磨'健'"强基固本的开局之年。（来源：昆药集团 2024 年年度报告摘要）独立视角：这是理解昆药集团 2025 年业绩下滑的最关键背景。央企入主后的"改革"，往往意味着：渠道梳理、品牌重塑、组织调整、去库存、计提减值……这些动作在短期内会牺牲利润、拖累收入，但目的是"刮骨疗毒"，为长期腾出空间。所以 2025 年的"难看"，未必是"基本面变坏"，更可能是"改革阵痛的代价"。 6.2 华润三九的持续增持：控股股东的"背书" 2026 年 5 月 14 日，昆药集团公告：为支持公司深耕银发健康赛道、传承精品国药、聚焦三七产业链，控股股东华润三九于 2026 年 4 月 27 日至 5 月 14 日通过集中竞价方式累计增持公司股份。（来源：证券时报网，2026-05-14）独立视角：控股股东在业绩承压期真金白银增持，是市场上少有但重要的积极信号——它传达的是大股东"看好长期、愿意托底"的态度。当然，这也不代表股价不会继续跌，而是说明"华润系"对昆药集团的战略定位是坚定的。 6.3 债务与融资：扩张期的资金动作 2026 年 6 月，昆药集团拟申请注册发行规模不超过 10 亿元的银行间债券（债务融资工具）。（来源：人民财讯，2026-06-08）独立视角：在业绩下滑、现金流承压的背景下，公司储备债务融资工具，是常见的"流动性管理"动作，也侧面印证了转型期的资金需求。 7. 财务体检：2024年的"历史新高"与2025年的"断崖" 7.1 近三年核心财务数据一览以下数据来自昆药集团历年年度报告（重述调整后口径）及公开财报：指标 2022年 2023年 2024年 2025年营业收入（亿元） 82.82 84.30 84.01 65.75 归母净利润（亿元） 3.83 5.41 6.48 3.50 扣非净利润（亿元） 2.51 3.35 4.19 1.07 经营现金流净额（亿元） 2.54 7.54 8.08 2.89 基本每股收益（元） 0.51 0.71 0.86 0.46* （注：*2025 年 EPS 为 0.46 元，来源新浪财经财务数据；其余来自昆药集团 2024 年年度报告"近三年主要会计数据"及 2025 年年报。2023/2024 数据为因并表华润圣火而重述调整后的口径。） 7.2 关键转折：从"双创新高"到"断崖式下滑" 把时间线捋顺，昆药集团的业绩轨迹非常清晰： - 2024 年（高光时刻）：营收 84.01 亿（微降 0.34%），但归母净利 6.48 亿（+19.86%）、扣非 4.19 亿（+25.09%），归母净利、扣非净利双创历史新高。（来源：昆药集团 2024 年年度报告） - 2025 年（断崖）：营收 65.75 亿（-21.74%），归母净利 3.50 亿（-46.00%），扣非 1.07 亿（-74.45%），经营现金流净额 2.89 亿（-64.21%）。（来源：昆药集团 2025 年年度报告）独立视角：这里有一个容易被忽视的"会计真相"——2024 年净利润新高，很大程度上包含了一次性的"并表红利"。公司 2024 年完成对华润圣火的同一控制下企业合并，按会计准则，华润圣火期初至合并日的净损益被计入"非经常性损益"（2024 年非经常性损益高达 2.29 亿，其中包括同一控制下合并产生的 2.44 亿）。所以2024 年的"6.48 亿"里，有一部分是会计处理的产物，而非纯经营利润。到了 2025 年，这个一次性红利消失，叠加主业承压，才出现了"断崖"。（来源：昆药集团 2024 年年报"非经常性损益"说明、中国证券报·中证网） 7.3 分季度透视：下半年扣非已现亏损更令人警醒的是季度数据。据深圳商报/读创财经报道，2025 年分季度看，每个季度净利均同比下滑，第三、第四季度扣非净利已出现亏损，2025 年下半年扣非净利亏损合计约 4399 万元。（来源：读创财经，2026-03-19）独立视角：这说明昆药集团的经营压力是逐季加深的，而不是单季偶发。零售端客流波动、集采执行不及预期、口服剂销量下滑，这些是持续性的基本面压力，而非一次性事件。 7.4 研发投入与分红 - 研发：2024 年研发投入 1.43 亿，占营收 1.7%，资本化率 25.4%。（来源：中国证券报·中证网） - 分红：2024 年度拟每 10 股派现 3 元（含税），分红总额约 2.27 亿元，现金分红占归母净利比例 35.04%。（来源：长江商报、昆药集团 2024 年年报）独立视角：即便业绩承压，昆药集团仍保持了分红传统，这符合央企子公司的"回报股东"导向，也给了长期投资者一定的安全垫。但 35% 的分红率，在中成药企业中属于中等偏稳健水平，谈不上特别慷慨。 8. 行业位置与竞争格局：三七赛道的"唯一玩家" 8.1 三七总皂苷制剂：血塞通的"独二家"地位在心脑血管中成药中，血塞通（三七总皂苷）是一个大品种。而血塞通软胶囊这个剂型，全国仅昆药集团和华润圣火两家生产，昆药集团收购华润圣火 51% 股权后，实际上将两家整合到了一起。（来源：长江商报，2025-03-13）独立视角：这是昆药集团最硬的一张"准入牌"。软胶囊剂型有专利/工艺壁垒，加上两家生产商的整合，意味着"三七总皂苷软胶囊"这个细分市场，竞争格局极其集中。这是"资源+剂型+准入"三重护城河的叠加。 8.2 三七产业链：从上游到下游的纵向整合昆药集团的三七业务，不是单纯"买三七做药"，而是向产业链上游（种植、提取）和下游（品牌、慢病服务）延伸。公司"聚焦三七产业链"被写入战略，是华润系看重的核心资产。（来源：昆药集团年报、证券时报网） 8.3 竞品格局：谁在跟昆药抢饭碗在心脑血管中成药/三七品类，昆药集团的主要竞争来自几个方向： - 同类三七总皂苷制剂的其他生产商（注射剂型企业较多，软胶囊剂型集中）； - 其他心脑血管中成药（如复方丹参滴丸——天士力、芪丹通脉片等）； - 中药集采带来的整体价格压力（中成药集采常态化推进，直接压制整个品类的利润空间）。（来源：昆药集团年报"可能面对的风险"、公开行业报道）独立视角：昆药集团的竞争壁垒在"三七 + 血塞通软胶囊"这个细分点上很硬，但在"整体心脑血管中成药"这个大品类里，它并非不可替代。真正的威胁不是某一家竞品，而是中成药集采的"无差别降价"——这会把整个三七品类的利润空间一起往下压。 9. 风险与隐忧：集采、单品依赖与转型阵痛这一节是全文最需要"客观泼冷水"的部分。昆药集团当前面临的，是三股风险的叠加：风险一：中成药集采常态化，利润空间被持续压缩中成药集采已常态化推进，医保控费持续深化。昆药集团的核心品种（血塞通等）面临明显的降价压力，直接侵蚀毛利。（来源：昆药集团 2025 年年报、证券时报·e公司《昆药集团今年一季度实现营收8.36亿元》，2026-04-24）风险二：单品依赖严重，"鸡蛋都在血塞通一个篮子里" 昆药集团高度依赖血塞通（三七总皂苷）这一单品线。当政策/需求波动，公司的营收、利润会同步剧烈震动——2025 年的"断崖"就是明证。（来源：昆药集团年报、深圳商报）风险三：转型阵痛尚未出清，短期业绩可能继续承压华润入主后的"三年融合""乐成改革"，涉及渠道梳理、品牌重塑、去库存、组织调整，短期会持续牺牲利润。公司自己也坦言"存量业务承压、增量业务尚处培育期"。（来源：昆药集团 2025 年年报）风险四：研发强度偏低，长期产品接力存疑 1.7% 的研发强度，意味着公司未来的"新增长点"更多依赖老品种二次开发和三七产业链延伸，而非全新重磅药。在老龄健康这个需要"产品+服务"双轮驱动的赛道里，昆药集团的"产品迭代能力"是需要持续观察的短板。（来源：中国证券报·中证网，此为笔者基于公开数据的分析判断）独立视角总结：昆药集团不是"突然变差"，而是"一家资源型老药企，在政策收紧 + 央企改造双重重压下，正在经历一次艰难的换挡"。它的风险，短期看是业绩，中期看是单品依赖，长期看是"能否从卖三七药，真正进化成服务老龄人口健康管理的平台"。 10. 独立判断与总结：它还是不是一只"黄金股" 10.1 一句话判断昆药集团的"黄金成色"，不在当前的利润表里，而在"三七产业链 + 银发健康 + 央企资源"这三张长期牌上；但短期，它必须先扛过转型阵痛的"至暗时刻"。 10.2 三个"好在"（护城河/确定性） 1. 好在"独"：三七总皂苷软胶囊"独二家"的准入壁垒，是很难被复制的硬护城河。 2. 好在"稳"：央企中国华润控股，华润三九持续增持，战略不漂移、治理规范、分红稳定。 3. 好在"坡长"：银发健康是未来十年确定性最强的赛道，而"三七"是中国老龄慢病管理里最具认知度的中药品类之一。 10.3 三个"隐忧"（风险/不确定性） 1. 隐忧在"价"：中成药集采会把三七品类的利润持续往下压，短期看不到反转。 2. 隐忧在"单"：过度依赖血塞通，抗风险能力弱，一次政策收紧就是一次"断崖"。 3. 隐忧在"转型"：从"卖药"升级到"老龄健康平台"，组织、渠道、产品接力都需要时间验证。 10.4 适合谁关注 - 医药从业者（代表/药师）：关注三七、血塞通、慢病中成药的人，昆药集团是一堂"单品如何撑起一家上市公司 + 集采如何反向重塑一家公司"的活教材。 - 关注"银发经济"的读者：昆药集团是 A 股少有的、把"银发健康"写进核心战略的央企子公司，是观察老龄健康产业落地的一个样本。 - 投资研究者：它提供了"央企入主改造"和"中成药集采冲击"两个经典案例的叠加样本，值得长期跟踪。 10.5 一句话记忆点 "三七是它的过去和现在，"银发健康"是它赌的未来；而夹在中间的，是一场还没走完的央企改造阵痛。" 11. 参考文献与数据来源本文所有事实与数据均来自公开信息，主要来源如下，供读者查证： 1. 昆药集团股份有限公司《2024 年年度报告》及《2024 年年度报告摘要》，上海证券交易所披露，2025-03-12。 2. 昆药集团股份有限公司《2025 年年度报告》，2026-03-19 披露（数据经读创财经/深圳商报引述）。 3. 昆药集团《2026 年半年度业绩预告》公告，2026-07-14。 4. 长江商报《昆药集团净利6.48亿创新高并表华润圣火存货周转率提升》，2025-03-13。 5. 中国证券报·中证网《昆药集团：2024年净利润同比增长19.86% 拟10派3元》，2025-03-11。 6. 深圳商报/读创财经《年报透视｜昆药集团内外夹击的2025：下半年扣非亏损4399万，核心产品承压》，2026-03-19。 7. 国泰海通证券《昆药集团（600422）2024年报业绩点评：融合稳步推进，改革潜力逐步释放》，2025-04-20。 8. 证券时报网《华润三九增持昆药集团看好银发健康前景信心不改》，2026-05-14。 9. 证券时报·e公司《昆药集团今年一季度实现营收8.36亿元银发健康布局积蓄长期动能》，2026-04-24。 10. 人民财讯《【公告】昆药集团：拟注册发行不超过10亿元银行间债券》，2026-06-08。 11. 新浪财经昆药集团（600422）财务摘要及行情数据。 12. 启信宝/国家企业信用信息公示系统：昆药集团工商信息、社保人数、历年营收利润数据。免责声明：本文内容基于公开信息整理，仅用于学习交流，不构成任何投资建议；文中涉及的前瞻性判断均为笔者个人观点，存在不确定性，请读者独立判断。若与上市公司官方披露存在出入，以官方披露为准。附章：几个值得深挖的"背景线索" 为了让读者真正"全面了解"昆药集团，以下补充几条贯穿全文、但容易被忽略的深层线索。 A. 青蒿素：昆药集团的"历史功勋章" 很多人不知道，昆药集团是中国青蒿素产业化的关键企业之一。青蒿素是中国科学家屠呦呦团队从黄花蒿中发现的抗疟有效成分，2015 年屠呦呦因此获得诺贝尔生理学或医学奖，是中国本土科学成果的最高荣誉之一。昆药集团的蒿甲醚系列，正是青蒿素的衍生物药物，长期出口并在全球抗疟领域发挥作用。公司披露，其双氢青蒿素磷酸哌喹片通过世界卫生组织（WHO）快速准入系统提交注册申请，并在多个国家获得批准。（来源：长江商报，2025-03-13）独立视角：青蒿素是昆药集团的"历史底气"，也是它的"技术牌面"——它证明这家公司不是只会做传统中成药，而是有天然药物开发、国际化注册的基因。但也要清醒看到：抗疟药的商业天花板有限，它更多是"荣誉资产"，而非"利润引擎"。当下真正给昆药集团赚钱的，还是三七。 B. 昆中药 1381 与"精品国药" 昆药集团旗下有"昆中药"这一老字号品牌资源。公司战略中的"传承精品国药"，指的就是把昆中药的历史经典名方（如参苓健脾胃颗粒、舒肝颗粒等）用现代标准重新做起来。 "1381"这一数字，对应的是昆中药的历史渊源（昆中药最早可追溯的历史年份）。公司把"昆中药 1381、777 协同并进"写入 2024 年年报，说明它在华润体系内被定位为"精品国药"的承载平台之一。（来源：昆药集团 2024 年年报摘要）独立视角：三七（心脑血管/慢病）与昆中药（消化/脾胃/精品国药）是昆药集团的"两条腿"。三七是当下主力，昆中药是潜在增长极。但中成药集采和零售客流波动，同样冲击了昆中药的消化类产品——2025 年消化系统产品营收同比下滑 42.68%。（来源：读创财经，2026-03-19） C. 员工与产能：一家"重资产"的老牌药企昆药集团合并报表员工人数约 5072 人（2025 年），总资产 117.74 亿元。它是一家典型的"重资产 + 生产型"药企，而非轻资产的研发型公司。（来源：启信宝工商数据、昆药集团年报）独立视角：重资产、多员工、老品种，这些特征意味着昆药集团的"腾挪空间"相对有限——它不可能像 biotech 那样快速砍管线、调结构。央企改造带来的人员优化、产能调整，也会是一个"慢而痛"的过程。这进一步解释了为什么它的转型阵痛期会拉得比较长。结语：一家值得被"看到"的老牌黄金药企写到结尾，回到栏目的初衷——"挖掘那些被市场忽视、却活得有厚度的药企"。昆药集团不是那种"财报亮眼、故事性感"的明星公司，恰恰相反，它正处在一个"旧的故事讲不动、新的故事还没讲完"的尴尬阶段。但也正是这样的公司，才配得上一篇万字深度的解读： - 它有历史（昆明制药厂、青蒿素、半个世纪）； - 它有壁垒（三七、血塞通软胶囊"独二家"）； - 它有靠山（央企华润）； - 它也有困境（集采、单品依赖、转型阵痛）。判断一家公司的价值，从来不只看它此刻的利润数字，而要看它手里攥着什么、脚下站在哪条赛道上、转型能不能走得通。昆药集团的这三层，我们已经在上面逐一拆开。至于结论——它是不是"黄金"，答案不在本文替读者下定论，而在读者看完这些白纸黑字的数据和逻辑之后，自己做判断。这，才是"客观"二字的应有之义。深度补充：把几个关键问题彻底讲透以下内容是对前文核心环节的深化，帮助读者建立更完整、更专业的认知。补一：三七这个"金不换"，到底金贵在哪里要真正理解昆药集团，必须先理解"三七"这个药材本身的商业逻辑。三七（学名 Panax notoginseng），与人参、西洋参同属五加科人参属，主产于云南文山及周边地区，素有"金不换""南国神草"之称。它的核心活性成分是三七总皂苷（PNS，Panax Notoginseng Saponins），具有活血化瘀、改善微循环等药理作用，是血塞通、血栓通等一系列心脑血管中成药的核心有效成分。三七有几个决定了它"商业价值"的特点： 1. 道地性强、产区集中：优质三七高度依赖云南文山等特定产区的土壤、气候，这构成了原料端的天然壁垒。谁掌握了道地产区的稳定原料供应，谁就掌握了成本和质量的话语权。 2. 生长周期长、供给有弹性：三七从种苗到采收需要较长时间（通常三年及以上），历史上多次出现"价高扩种—过剩暴跌"的周期波动，这决定了上游种植的周期性风险。 3. 下游应用广、需求刚性：心脑血管疾病是中国致死致残的首位病因，随着人口老龄化，三七类制剂的潜在需求长期向上。（本节为笔者基于公开药学常识与行业资料整理，药理表述以药品说明书及权威文献为准。）独立视角：昆药集团押注三七，本质是押注"老龄化的确定性需求 + 道地药材的资源壁垒"这两个长期变量。但也正因为三七种植的周期性，公司的原料成本并非完全可控——上游三七价格的历史大起大落，会传导到公司的毛利率。这是隐藏在"护城河"叙事背后的另一个真实风险。补二：血塞通的作用机制与临床价值，一句话讲清楚血塞通的主要成分三七总皂苷，其药理作用集中在"活血化瘀、通脉活络"——用于缺血性脑血管病（如脑梗后遗症）、心血管疾病等的辅助治疗。从剂型上看，血塞通有两条主要路线： - 注射剂型（注射用血塞通/冻干粉针）：医院端使用，起效快，但受"中药注射剂限用、医保控费、重点监控"等政策影响更大——这正是 2024 年血塞通注射剂销量大幅下滑的政策背景。 - 口服剂型（血塞通软胶囊/滴丸等）：零售和院外市场使用，患者依从性好，但受到"药店统筹支付处方管控、慢病病种限制"的直接冲击。（药理及剂型表述为笔者基于公开药品信息的整理，具体以药品说明书为准。）独立视角：看懂"注射剂受控、口服剂受限"这一条，就看懂了昆药集团 2025 年业绩下滑的微观机制——它的两大剂型，一个被医院端政策压，一个被零售端政策压，两头挤。这不是产品本身失效，而是"支付端政策"对"中成药慢病用药"的全面收紧。补三：中成药集采，是昆药集团最大的"时代变量" 要客观评价昆药集团，绕不开"中成药集采"这个大背景。与化学药集采不同，中成药集采因为"成分复杂、质量评价难、品牌差异大"，推进节奏相对谨慎，但方向明确、不可逆。它带来的核心影响是： 1. 价格中枢下移：中标品种的降价幅度普遍不小，直接压缩药企的利润空间。 2. 渠道逻辑重构：过去依赖"高毛利、多层级经销、药店高推"的中成药，被迫转向"集采中标、以价换量、院内院外整合"。 3. 品类洗牌加速：缺乏品牌壁垒、同质化严重的中成药品种会被快速边缘化，而有品牌、有资源、有渠道的龙头企业反而通过集采扩大份额。（来源：昆药集团年报"可能面对的风险"、证券时报·e公司、国泰海通证券研报等。）独立视角：集采对昆药集团是一把"双刃剑"。短期是利空——血塞通等核心品种降价、利润承压；但长期可能是利好——因为集采会加速中小竞争者出清，而昆药集团作为"三七总皂苷软胶囊独二家 + 央企渠道"的玩家，理论上更有能力承接集采后的市场集中。关键问题是：昆药集团能不能在"阵痛期"里活到"收获期"。这也是它当前股价和业绩之间最大的预期差所在。补四：华润三九想要昆药集团的，到底是什么很多读者会问：华润三九收购昆药集团 28% 股份花了 29.02 亿，它图什么？拆开看，华润的逻辑至少有四层： 1. 品类卡位：华润三九本身是"OTC + 中药"龙头，但在"心脑血管中成药 + 三七"这个细分，它需要昆药集团的血塞通来补位。 2. 资源整合：三七产业链（道地药材 + 提取工艺 + 品牌）是稀缺的战略资源，整合进华润体系，能放大华润在中药原料和慢病领域的整体优势。 3. 品牌矩阵：昆中药（精品国药）、血塞通（三七龙头）等品牌，能丰富华润三九的"大健康品牌矩阵"。 4. 银发健康入口：华润在"银发经济"上有全景布局（医药、健康、养老、消费），昆药集团是其"医药端的老龄健康入口"之一。（来源：昆药集团公告、证券时报网、长江商报，此为笔者基于公开信息的归纳分析。）独立视角：理解了华润的这四层意图，就能明白——昆药集团的"长期价值"，很大程度取决于它在华润"银发健康生态"里能不能被真正激活。如果只是财务并表、渠道共享，昆药集团难以摆脱"三七依赖"；但如果华润能把它变成"慢病管理 + 老龄健康服务"的完整入口，昆药集团的想象空间就完全不同。这笔"29.02 亿的收购"，赌的不是现在，是未来。附录：昆药集团核心信息速查卡项目信息公司全称昆药集团股份有限公司股票代码 600422.SH 曾用简称昆明制药成立时间 1951 年 3 月（前身昆明制药厂）上市时间 2000 年 12 月（上交所）实际控制人中国华润有限公司（央企）控股股东华润三九医药股份有限公司（持股约 28.05%）核心战略银发健康产业引领者核心资产三七产业链、血塞通系列、昆中药员工人数约 5072 人（2025 年合并报表）（数据来源：昆药集团 2024/2025 年年度报告、启信宝工商数据。）补遗：血塞通的前世今生，与三七产业的"周期宿命" 血塞通过去二十年：从小品种到"慢病大单品" 血塞通（三七总皂苷）并非一夜爆红，而是伴随中国心脑血管疾病负担上升、慢病管理意识觉醒，一步步成长为中药大品种的。在早期，血塞通主要在医院端以注射剂型使用；随着"中药注射剂安全争议"和医保政策收紧，注射剂型的使用被逐步压缩，口服剂型（软胶囊、滴丸）承接了部分需求，转向院外零售和慢病长期调理场景。昆药集团在这个过程中，凭借"三七总皂苷软胶囊独二家"的剂型壁垒，占据了口服剂型的有利位置。（来源：国泰海通证券研报、长江商报，剂型演变经笔者基于公开信息整理。）独立视角：血塞通的"前世今生"，其实是一条清晰的"从医院注射剂 → 零售口服剂"的迁移曲线。昆药集团算得上踩对了半程节奏，却也在下半程遭遇了"零售统筹支付收紧"的政策逆风。它的命运，始终与"中成药慢病用药的支付政策"深度绑定。三七种植的"周期宿命"，是悬在昆药头上的一把剑前面提到三七种植的周期性，这里有必要展开，因为它直接影响昆药集团的毛利率和存货价值。三七是多年生药材，历史上价格波动极大。典型规律是：高价刺激农民扩大种植 → 三四年后集中上市 → 供给过剩 → 价格暴跌 → 农民亏损弃种 → 供给收缩 → 价格回升，如此循环。昆药集团作为三七产业链的深度参与者，上游原料价格的剧烈波动，会直接体现在它的营业成本和存货跌价准备上。（本节为笔者基于公开行业资料整理。）独立视角：投资者看昆药集团，往往会盯着"血塞通卖了多少"，却容易忽略"三七原料价格"这个隐形变量。事实上，三七价格的周期波动，可能比集采降价更隐蔽、更直接地影响它的毛利。这是研究昆药集团时，一个容易被忽视、却相当重要的专业观察点。昆药集团的"国际化底色"：不止是出口，更是准入能力昆药集团的国际化，不是很多创新药公司那种"License-out 卖管线换钱"，而是更传统、也更扎实的"药品全球注册准入"。公司披露的数据显示，其海外注册成果丰硕：提交 131 份申请获 30 个批文；双氢青蒿素磷酸哌喹片通过 WHO 快速准入系统提交注册申请 38 份（22 个国家），已获准 7 个国别注册批准；三七制剂血塞通已在 15 个国家获得准入，并为血塞通软胶囊在美国、欧洲等法规市场上市做前期准备。2024 年海外营收 1.4 亿元，同比增长 21.52%。（来源：长江商报，2025-03-13）独立视角：这一组数据，是昆药集团隐藏的"硬实力"——它具备把中药/植物药注册到全球法规市场的能力。虽然当前海外营收体量还小（1.4 亿），但"准入能力"是一张长期牌：一旦三七类产品在国际市场打开缺口，昆药集团是有资格、有能力承接的少数中国企业之一。这是它区别于绝大多数"只会内销"的中成药厂的地方。附记：为什么这一期，我们讲一个"正在阵痛"的公司栏目开张第一期，我没有选一家"财报漂亮、故事性感"的公司，而是选了一家"正在阵痛"的公司。原因很简单：真正能让人"全面了解一家药企"的，恰恰是那些处于转折点的公司。一家顺风顺水的公司，它的优势人人都看得见；而一家正在换挡的公司，它的护城河、它的风险、它的战略、它的代价，才全部摊开在阳光下，值得被细细拆解。昆药集团，就是这样一个样本。它足够老（有历史）、足够独（有三七和血塞通）、足够稳（有央企靠山）、也足够痛（有集采和转型的双重压力）。看懂它，你就看懂了中国中成药行业在"老龄化红利"与"政策收紧"之间的真实博弈。而这，正是「药说药企」想长期做下去的事——不吹不黑，把一家公司讲透，把判断的钥匙交给读者。（「药说药企」栏目 · 第 001 期 · 昆药集团 · 全文终）策划制作：药说团队

2026-06-08

·北京医学感染与传染研究

柳叶刀传染病学 26卷 1-6期

THE LANCET Infectious Diseases. Volume 26Number 1 柳叶刀传染病学 26卷 1期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Urgent need for infection prevention and control in prisons 监狱中感染预防和控制的迫切需求 The Lancet Infectious Diseases The Lancet Infectious Diseases Vol 26(1):p1 COMMENT（述评） 2 Now is the time to integrate serology into routine infectious disease surveillance 现在是时候将血清学纳入常规传染病监测了 Simon Cauchemez The Lancet Infectious Diseases Vol 26(1):p2 3 Reassessing sotrovimab's role in COVID-19: insights and implications 重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示 Daniele Focosi,Fabrizio Maggi The Lancet Infectious Diseases Vol 26(1):p3 4 Shaping opportunities for future clinical trials in tuberculosis 为未来结核病临床试验创造机会 Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich The Lancet Infectious Diseases Vol 26(1):p5 5 Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda 乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化 Arjen M Dondorp The Lancet Infectious Diseases Vol 26(1):p6 6 A safe start for PfSPZ Vaccine, but efficacy in children remains elusive PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸 Nicholas Aderinto,Temitomi Jane Oyedele The Lancet Infectious Diseases Vol 26(1):p8 7 Rifasutenizol-based triple therapy for Helicobacter pylori infection 以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染 Jinnan Chen,Hong Lu The Lancet Infectious Diseases Vol 26(1):p9 8 The smallest faith 最渺小的信念 Steven A Pergam The Lancet Infectious Diseases Vol 26(1):p11 9 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease 新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标 Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson The Lancet Infectious Diseases Vol 26(1):p13 10 Strengthening global preparedness and response to arboviral disease threats: a call to action 加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁 WHO Global Arbovirus Initiative Technical Advisory Group 世界卫生组织全球虫媒病毒倡议技术咨询小组 The Lancet Infectious Diseases Vol 26(1):p15 11 Introducing our cover artist for 2026: Daria Lada 介绍我们2026年的封面艺术家：达里亚·拉达 Marco De Ambrogi The Lancet Infectious Diseases Vol 26(1):p17 Correspondence（读者来信） 12 Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2 新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况 Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases Vol 26(1):e1 13 Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响 Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens The Lancet Infectious Diseases Vol 26(1):e3 14 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致 Nader Ebrahimi,Amir Ghaemi The Lancet Infectious Diseases Vol 26(1):e6 15 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复 Frank Aarestrup,Marion Koopmans The Lancet Infectious Diseases Vol 26(1):e7 16 Time to tackle vaccine–HLA associations with artificial intelligence 是时候用人工智能解决疫苗-人类白细胞抗原关联问题了 Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington The Lancet Infectious Diseases Vol 26(1):e8 Corrections（更正） 17 Correction to Lancet Infect Dis 2025; published online Oct 29. 《柳叶刀-传染病》2025年更正；在线发表于10月29日 https://doi.org/10.1016/S1473-3099(25)00466-9 The Lancet Infectious Diseases Vol 26(1):e9 18 Correction to Lancet Infect Dis 2025; published online Oct 27. 《柳叶刀-传染病》2025年更正；在线发表于10月27日 https://doi.org/10.1016/S1473-3099(25)00546-8 The Lancet Infectious Diseases Vol 26(1):e9 19 Correction to Lancet Infect Dis 2025; 25: 1084–96 《柳叶刀-传染病》2025年更正；25卷：1084-1096页 The Lancet Infectious Diseases Vol 26(1):e9 20 Correction to Lancet Infect Dis 2025; published online Nov 10. 《柳叶刀-传染病》2025年更正；在线发表于11月10日 https://doi.org/10.1016/S1473-3099(25)00550-X The Lancet Infectious Diseases Vol 26(1):e9 Newsdesk（新闻台） 21 Highlights of IDWeek 2025 2025年IDWeek亮点 Phoebe Hall The Lancet Infectious Diseases Vol 26(1):e10 22 WHO publishes update on global antibiotic resistance 世界卫生组织发布全球抗生素耐药性最新情况 Timothy Jesudason The Lancet Infectious Diseases Vol 26(1):e11 23 European Commission to fund new medicines for dengue 欧盟委员会资助登革热新药研发 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):e12 24 Second report from the UK Covid-19 Inquiry 英国新冠肺炎调查第二次报告 Talha Burki The Lancet Infectious Diseases Vol 26(1):e13 25 Infectious disease surveillance update 传染病监测最新情况 Cahal McQuillan The Lancet Infectious Diseases Vol 26(1):e14 26 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases Vol 26(1):e15 Obituary（讣告） 27 Jean Louis Abdourahim Ndiaye 让·路易斯·阿卜杜拉希姆·恩迪亚耶 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):p19 Profile（人物介绍） 28 Fortunate Machingura—tackling climate change and disease 福图纳特·马辛古拉——应对气候变化与疾病 Tony Kirby The Lancet Infectious Diseases Vol 26(1):p20 Media Watch（媒体观察） Book（书籍） 29 The social and political drivers behind pandemics 大流行背后的社会和政治驱动因素 Emma Louise Fabiani The Lancet Infectious Diseases Vol 26(1):p21 Articles（论著） 30 Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究 Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek The Lancet Infectious Diseases Vol 26(1):p22 31 Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验 RECOVERY Collaborative Group RECOVERY协作组 The Lancet Infectious Diseases Vol 26(1):p34 32 A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验 John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team The Lancet Infectious Diseases Vol 26(1):p46 33 Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析 Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar The Lancet Infectious Diseases Vol 26(1):p55 34 Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验 Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka The Lancet Infectious Diseases Vol 26(1):p67 35 Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验 Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller The Lancet Infectious Diseases Vol 26(1):p79 36 Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究 Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda The Lancet Infectious Diseases Vol 26(1):p91 37 Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验 Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group The Lancet Infectious Diseases Vol 26(1):p101 Series（专题研讨会） 38 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Innovation in active and passive immunisation of people who are immunocompromised: a call to action 免疫功能低下人群主动和被动免疫接种的创新：行动呼吁 Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa The Lancet Infectious Diseases Vol 26(1):e16 39 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship 应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理 Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo The Lancet Infectious Diseases Vol 26(1):e30 Review（综述） 40 Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project 揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述 Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro The Lancet Infectious Diseases Vol 26(1):e49 Personal View（个人观点） 41 Azithromycin mass drug administration: balancing survival benefits and risks in children 阿奇霉素大规模药物给药：平衡儿童生存益处与风险 Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro The Lancet Infectious Diseases Vol 26(1):e62 Clinical Picture（临床影像） 42 Unexpected finding in a 17-year-old female undergoing screening colonoscopy 17岁女性接受筛查结肠镜检查时的意外发现 Ziheng Calvin Xu,Ethan Tan,Mayur Garg The Lancet Infectious Diseases Vol 26(1):e75 THE LANCET Infectious Diseases. Volume 26Number 2 柳叶刀传染病学 26卷 2期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Call for letters 征稿启事 The Lancet Infectious Diseases The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111 Comment（述评） 2 Long COVID is here to stay—even in children 长期新冠症状将持续存在——即使在儿童中亦是如此 Danilo Buonsenso The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112 3 Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment 利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用 Ming Hong Choi,Ivan Fan Ngai Hung The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113 4 A new monoclonal in the arMAMentarium against malaria 抗疟“武器库”中的新型单克隆抗体 Freia-Raphaella Lorenz,Matthew B B McCall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115 5 Household transmission of mpox in Africa: limited in adults but more prevalent in children 非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍 Oriol Mitjà,Michael Marks The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117 6 The lasting lessons of mpox: infection, vaccination, and immune memory 猴痘带来的持久教训：感染、疫苗接种和免疫记忆 Raianna Fantin,Camila H Coelho The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118 7 Xpert-Ultra for diagnosing asymptomatic tuberculosis Xpert-Ultra用于诊断无症状结核病 Xia Yu,Hairong Huang The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120 8 The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action 基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动 David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122 Correspondence（读者来信） 9 Spillover in dengue trials 登革热试验中的溢出效应 Thomas A Smith,Samuel I Watson The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77 10 Spillover in dengue trials – Author's reply 登革热试验中的溢出效应——作者回复 Fernando Abad-Franch The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78 11 Updating the traditional voriconazole trough concentration range 传统的伏立康唑谷浓度范围更新 Rongqiang Liao,Xiaoyuan Zheng The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79 12 Updating the traditional voriconazole trough concentration range – Authors' reply 传统的伏立康唑谷浓度范围更新——作者回复 Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80 13 Clinical course and neurological profile of Kyasanur Forest disease 基萨努尔森林病的临床病程和神经特征 Nitin Gupta,Tirlangi Praveen Kumar The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82 Corrections（更正） 14 Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7 对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 15 Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4 对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 Newsdesk（新闻台） 16 Promising early data for sorfequiline 索氟维林早期数据令人鼓舞 Ed Holt The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84 17 Highlights from ASTMH 2025 2025年美国热带医学与卫生学会年会亮点 Marco De Ambrogi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85 18 Brazil approves domestic single-shot dengue vaccine 巴西批准国产单剂登革热疫苗 Marcia Triunfol The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86 19 CDC cuts to childhood vaccine recommendations 美国疾控中心削减儿童疫苗接种建议 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87 20 WHO launches unified plan for coronaviruses 世界卫生组织启动冠状病毒统一计划 Talha Burki The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88 21 Infectious disease surveillance update 传染病监测更新 Cahal McQuillan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89 22 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90 Obituary（讣告） 23 Walter Dowdle 沃尔特·道德尔 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124 Profile（人物简介） 24 Katie Anders—improving global dengue control 凯蒂·安德斯——改善全球登革热防控 Tony Kirby The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125 Media Watch（媒体观察） Film（电影） 25 Eliminating Guinea worm 根除麦地那龙线虫 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126 Articles（论著） 26 Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study 奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127 27 Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial 口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验 William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139 28 Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial 头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验 David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148 29 Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验 single-blind, randomised, controlled, dose-ranging, phase 2 trial Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160 30 Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial 人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验 Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170 31 Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study 布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究 Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182 32 Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study 比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究 Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190 33 Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study 乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究 Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203 Review（综述） 34 Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge 侵袭性A组链球菌感染：从2022-23年激增中吸取的教训 Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91 35 A clinical practice guideline for tuberculous meningitis 结核性脑膜炎临床实践指南 Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96 36 Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults 缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症 Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112 Personal View（个人观点） 37 A transformation in cholera surveillance 霍乱监测的变革 Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124 Clinical Picture（临床图像） 38 Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing 尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展 Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130 THE LANCET Infectious Diseases. Volume 26Number 3 柳叶刀传染病学 26卷 3期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL（社论） 1 Promises and challenges of AI in infectious diseases 人工智能在传染病领域的承诺与挑战 The Lancet Infectious Diseases The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213 COMMENT（述评） 2 More real-world evidence for RSV vaccines in the global community 全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据 Kristina L Bajema,Wesley H Self The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214 3 Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet 猴痘快速诊断抗原检测及分散检测的必要性——尚待完善 Daniel Mukadi-Bamuleka,Kevin K Ariën The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215 4 Solving the data bottleneck for artificial intelligence in infectious diseases 解决传染病人工智能领域的数据瓶颈问题 Cesar de la Fuente-Nunez The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217 5 Artificial intelligence and One Health: potential for spillover prediction? 人工智能与“同一健康”理念：能否预测病原体外溢？ Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219 6 Artificial intelligence in the development of vaccines for infectious diseases 人工智能在传染病疫苗研发中的应用 Steve Black,Shabir A Madhi,Rino Rappuoli The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221 7 Peer review at The Lancet Infectious Diseases in 2025 2025年《柳叶刀-传染病学》期刊专家评审 Ursula Hofer The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223 8 Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025 感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家 The Lancet Infectious Diseases Editors The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132 CORRESPONDENCE（读者来信） 9 Methodological considerations in the attribution of long COVID to first or second infection 首次或二次感染导致长期新冠症状的方法学考量 Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139 10 Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply 首次或二次感染导致长期新冠症状的方法学考量——作者回复 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141 11 Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答 Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142 12 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者 Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144 13 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复 David L Paterson,Abdullah T Aslan,Patrick N A Harris The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145 CORRECTIONS（更正） 14 Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0 《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0 The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 15 Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X 《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 NEWSDESK（新闻台） 16 Rabies an increasing threat in Ukraine 乌克兰狂犬病威胁日益加剧 Ed Holt The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147 17 People needing trachoma interventions at record low 需要沙眼干预措施的人数创历史新低 Timothy Jesudason The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148 18 Uneven STI response in EU/EEA countries 欧盟/欧洲经济区国家性传播感染应对措施不均衡 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149 19 Controversial HBV vaccine trial in Guinea-Bissau halted 几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停 Talha Burki The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150 20 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151 OBITUARY（讣告） 21 Ivan Hirsch 伊万·赫希 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224 PROFILE（人物介绍） 22 Reem Abu Shomar— championing water safety in Gaza 里姆·阿布·舒马尔——加沙地带水安全倡导者 Tony Kirby The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225 MEDIA WATCH（媒体观察） Book（书籍） 23 A prescription for public health literacy 提升公众健康素养的良方 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226 Book（书籍） 24 Imagining the inevitable 想象不可避免之事 Cahal McQuillan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227 Film（电影） 25 Women's autonomy, safe sex and HIV prevention 女性自主权、安全性行为与艾滋病预防 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228 ARTICLES（论著） 26 Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study 英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究 Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229 27 Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial 印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验 Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239 28 Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial 血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析 Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250 29 Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study 刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究 Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260 30 Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis 伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析 Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270 31 Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析 GBD 2023 Chagas Disease and RAISE Study Collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284 32 Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial 乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验 Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302 33 Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial 美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验 Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314 SERIES（研讨会） Artificial Intelligence and Infectious Diseases 人工智能与传染病 34 Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice 人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架 Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152 35 Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives 人工智能与传染病诊断：现状与未来展望 Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168 36 Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery 人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现 Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181 REVIEW（综述） 37 Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia 血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议 Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193 CLINICAL PICTURE（临床图像） 38 Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection 人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染 Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B Spiller,Baharak Afshar The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207 THE LANCET Infectious Diseases. Volume 26Number 4 柳叶刀传染病学 26卷 4期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 GoGoVax dispels hopes for gonorrhoea vaccination GoGoVax让淋病疫苗的希望破灭 The Lancet Infectious Diseases The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329 COMMENT（述评） 2 Do the benefits of universal screening outweigh the harms? 全民筛查的益处是否大于害处？ Alanna N Gillespie,Emma Webb,Valerie Sung The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330 3 Chikungunya in Brazil: vaccination strategies informed by mathematical modelling 巴西基孔肯雅热：基于数学建模的疫苗接种策略 José Lourenço,Marta Giovanetti The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331 4 Chikungunya adolescent vaccination and the distinct risk–benefit landscapes 青少年接种基孔肯雅热疫苗及独特的风险-获益情况 Ernesto T A Marques,Simon Barratt-Boyes The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333 5 Circulation of clade Ib mpox outside of Africa—are we prepared? 非洲以外地区Ib分支猴痘的传播——我们准备好了吗？ Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334 6 I worked at WHO: the USA leaving will not make America healthier 我曾在世卫组织工作：美国退出不会让美国更健康 Krutika Kuppalli The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336 CORRESPONDENCE（读者来信） 7 Maternal views on RSV vaccination in the UK's second season 英国第二季呼吸道合胞病毒疫苗接种的产妇观点 Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209 8 Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters 利用COVID-19 LP.8.1 mRNA加强针克服免疫印记 Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212 CORRECTIONS（更正） 9 Correction to Lancet Infect Dis 2025; published online Nov 27. https://doi.org/10.1016/S1473-3099(25)00605-X 《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 10 Correction to Lancet Infect Dis 2026; 26: 343–61 《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 11 Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3 《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 12 Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9 《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 NEWSDESK（新闻台） 13 UK loses measles elimination status as cases rise 随着病例增加，英国失去麻疹消除地位 Priya Venkatesan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215 14 Brazil launches implementation study of lenacapavir 巴西启动来那卡帕韦实施研究 Tony Kirby The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216 15 Clade Ib mpox in southwest Indian Ocean islands 西南印度洋岛屿出现Ib分支猴痘 Esther Nakkazi The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217 16 EMA approves combined COVID-19 and flu mRNA vaccine 欧洲药品管理局批准COVID-19和流感联合mRNA疫苗 Talha Burki The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218 17 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219 OBITUARY（讣告） 18 Nicholas John White 尼古拉斯·约翰·怀特 Sanjeet Bagcchi The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339 PROFILE（人物简介） 19 Katharina Kranzer—led by curiosity, committed to capacity 卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力 Tony Kirby The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340 MEDIA WATCH（媒体观察） Film（电影） 20 Leishmaniasis: a story of two continents 利什曼病：两个大陆的故事 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341 Book（书籍） 21 Finding your voice in a world of uncertainty 在不确定的世界中找到自己的声音 Carrie Fielden The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342 ARTICLES（论著） 22 Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析 GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators GBD 2023下呼吸道感染和抗菌素耐药性协作组 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343 23 Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis 英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析 Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362 24 Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study 法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究 Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374 25 Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study 以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究 Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384 26 Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study 使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究 Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394 27 The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study 巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究 Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406 28 Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil 青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果 Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417 29 National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study 孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究 Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429 REVIEW（综述） 30 Autoantibodies in long COVID: a systematic review 长新冠中的自身抗体：一项系统综述 Fabian Wilhelm,Janne Cadamuro,Sylvia Mink The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220 31 Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE) 登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE） Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231 PERSONAL VIEW（个人观点） 32 Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali 通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解 Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245 GRAND ROUND（大查房） 33 Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned 儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训 Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259 CLINICAL PICTURE（临床图像） 34 Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis 肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎 Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268 THE LANCET Infectious Diseases. Volume 26Number 5 柳叶刀·传染病学26卷 5期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 How are vaccine recommendations made? 疫苗建议是如何制定的？ The Lancet Infectious Diseases The Lancet Infectious Diseases. May 2026，Vol 26(5)：p439 COMMENT（述评） 2 First efficacy evidence for a multistage malaria vaccine targeting infection and transmission 针对感染和传播多阶段的疟疾疫苗首次显示出有效性证据 Gemma Moncunill,Carlota Dobaño The Lancet Infectious Diseases. May 2026，Vol 26(5)：p440 3 Lassa viral dynamics: implications for missed diagnosis 拉沙病毒动态：对漏诊的影响 Chinwe Lucia Ochu,William Douglas Evans The Lancet Infectious Diseases. May 2026，Vol 26(5)：p441 4 Nirsevimab over two RSV seasons: do the findings align with expectations? 两个呼吸道合胞病毒（RSV）季节中Nirsevimab的应用情况：研究结果是否符合预期？ Corinne Levy,Robert Cohen The Lancet Infectious Diseases. May 2026，Vol 26(5)：p443 5 Improving antimalarial therapeutic efficacy studies 提高抗疟治疗疗效研究的质量 Philip J Rosenthal The Lancet Infectious Diseases. May 2026，Vol 26(5)：p444 6 The case for routine patient review in long COVID research 在长期新冠研究中开展常规患者评估的理由 Letícia Soares,C H Romatowski,Gina Assaf,Chloé de Canson The Lancet Infectious Diseases. May 2026，Vol 26(5)：p446 CORRESPONDENCE（读者来信） 7 When mpox is not mpox: varicella and measles in DR Congo 当猴痘并非猴痘时：刚果民主共和国的水痘和麻疹病例 Levi Bugwaja,Nathan Banzi,Trust Faraja Mukika,Patrick Kazuba Bugale,Patrick Musole Bugeme,Emmanuel Biragi Nzenze,Heshima Lajeri Nzirimo,Salomon Mashupe Shangula,Justin Bengehya,Willy Kasi,Krutika Kuppalli,Camille Escadafal,Daniel Mukadi-Bamuleka,Jackie Knee,Jules Jackson,Elizabeth C Lee,Andrew S Azman,Espoir Bwenge Malembaka The Lancet Infectious Diseases. May 2026，Vol 26(5)：e209 8 Mpox virus in human breastmilk and tecovirimat pharmacokinetics: implications for postnatal transmission 人乳中的猴痘病毒及特考韦瑞药代动力学：对产后传播的影响 Francesca Colavita,Massimo Tempestilli,Silvia Meschi,Carla Pittini,Martina Rueca,Giuseppe Sberna,Fabrizio Carletti,Simone Lanini,Silvia Cammisa,Giulia Paviotti,Lorenza Driul,Miriam De Vito,Cesare Ernesto Maria Gruber,Marco Cotrufo,Eleonora Cimini,Valentina Mazzotta,Andrea Antinori,Carlo Tascini,Fabrizio Maggi,Licia Bordi The Lancet Infectious Diseases. May 2026，Vol 26(5)：e211 CORRECTIONS（更正） 9 Correction to Lancet Infect Dis 2026; 26: 522–34 对《柳叶刀-传染病》2026年第26卷第522–34页的更正 The Lancet Infectious Diseases. May 2026，Vol 26(5)：e213 NEWSDESK（新闻台） 10 New WHO recommendations for tuberculosis diagnosis 世卫组织新的结核病诊断建议 Timothy Jesudason The Lancet Infectious Diseases. May 2026，Vol 26(5)：e214 11 New report assesses antimicrobial pipeline 新报告评估抗菌药物研发管线 Manjulika Das The Lancet Infectious Diseases. May 2026，Vol 26(5)：e215 12 Meningitis B outbreak in England 英格兰B型脑膜炎暴发 Tony Kirby The Lancet Infectious Diseases. May 2026，Vol 26(5)：e216 13 WHO reports on health of migrants and refugees 世卫组织发布移民和难民健康报告 Talha Burki The Lancet Infectious Diseases. May 2026，Vol 26(5)：e217 14 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. May 2026，Vol 26(5)：e218 OBITUARY（讣告） 15 Christian C Patrick 克里斯蒂安·C·帕特里克 Sanjeet Bagcchi The Lancet Infectious Diseases. May 2026，Vol 26(5)：p448 PROFILE（人物简介） 16 Eizo Takashima—developing a new class of malaria vaccines 高石荣三——开发新型疟疾疫苗 Tony Kirby The Lancet Infectious Diseases. May 2026，Vol 26(5)：p449 MEDIA WATCH（媒体观察） Book（书籍） 17 Feminism and the AIDS epidemic 女权主义与艾滋病流行 Charlotte Day The Lancet Infectious Diseases. May 2026，Vol 26(5)：p450 ARTICLES（论著） 18 Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection study ProC6C-AlOH/Matrix-M预防恶性疟原虫感染和蚊子传播的有效性：一项2期随机对照人体疟疾感染研究 Mamady Kone,Jordan Plieskatt,Moussa Thienta,Bourama Kamate,Ebenezer A Ofori,Markus Gmeiner,Bayaya Haidara,Moussa B Kanoute,Bakary Traore,Ousmane A Poudiouguo,Hawa S Bayogo,Ibrahim Diarra,Karim Bengaly,Amatigue Zeguime,Daman Sylla,Adama Sacko,Stephen L Hoffman,Matthew B B McCall,Michael Theisen,Issaka Sagaraon behalf of the ProC6C Study Group The Lancet Infectious Diseases. May 2026，Vol 26(5)：p451 19 The effectiveness of long-lasting spatial repellent emanators against malaria in humanitarian crisis settings in northern Nigeria: a two-arm pragmatic, open-label, controlled trial 长效空间驱蚊剂在尼日利亚北部人道主义危机环境中预防疟疾的有效性：一项双臂实用、开放标签、对照试验 Richard James Allan,Ramona Scherrer,Sara Estecha-Querol,David Weetman,Laura Paris,Umar Ba'abba Goni,Fatima Idris Abdulhamid,Blaise Nfornuh Alenwi,Sajjad Ahmad,Chad L Cross,Garba Mohammed Ashir,Mala Waziri,Godwin Ntadom,Louisa Alexandra Messenger The Lancet Infectious Diseases. May 2026，Vol 26(5)：p464 20 Lassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia 拉沙热症状、病毒动态和宿主免疫反应（PREPARE）：利比里亚一项前瞻性观察队列研究 David A Wohl,Carwolo Pewu,Chanhwa Lee,Emmanuel Kerkula,Martha Gayflowu,Nukal Doetein,Katie R Mollan,Taylor J Krajewski,Becky Straub,Alfred Flomo,Amara Fofana,Stanley Kerkula,Thomas Sumo,Alexander Sampson,Samuel Vouh,Fred Flomo,McKenzie A Colt,Thomas Remont,Eleanor Rose Watts,Marta Zizek,Catherine Nimely,Minnie Ricks,Jefferson Sibley,William A Fischer II The Lancet Infectious Diseases. May 2026，Vol 26(5)：p475 21 Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study B群链球菌疫苗（GBS-AlpN）在孕妇及其婴儿中的免疫原性和安全性：一项2期、多中心、观察者设盲、随机、安慰剂对照研究 Paul T Heath,Ntokozo Zuma-Gwala,Rikke Bek Helmig,Elizea Horne,Anette Kjærbye-Thygesen,Mie Korslund Wiinblad Crusell,Maphoshane Nchabeleng,Renate Strehlau,Mohammed R Khalil,Christine E Jones,Jorne Biccler,Jeannett Dimsits,Bengt Johansson-Lindbom,Per B Fischer,Lidia Oostvogels,Shabir A Madhion behalf of the MVX0004 study group The Lancet Infectious Diseases. May 2026，Vol 26(5)：p486 22 Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial 单剂量口服减毒霍乱活疫苗PanChol的安全性和免疫原性：一项1a期、双盲、随机、安慰剂对照试验结果 Deborah R Leitner,Stephen R Walsh,Masataka Suzuki,Michaël Desjardins,Alisse Hannaford,Amy C Sherman,Hannah Levine,Lena Carr,Elliot Hammerness,Akina Osaki,Emily Sullivan,Bryan Wang,George I Balazs,Jun Bai Park Chang,Damien M Slater,Nirajan Puri,Carole J Kuehl,Wilbur H Chen,Jason B Harris,Steven Piantadosi,Lindsey R Baden,Matthew K Waldoron behalf of the PanChol study group The Lancet Infectious Diseases. May 2026，Vol 26(5)：p497 23 Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial 晚期艾滋病患者使用整合酶抑制剂与蛋白酶抑制剂治疗（LAPTOP）：一项多国、随机、开放标签、非劣效性试验 Georg M N Behrens,Lambert Assoumou,Geoffroy Liegeon,Andrea Antinori,Rafael Micán,Francesco G Genderini,Frank A Post,Jürgen K Rockstroh,Lisa Hamzah,Pere Domingo,Adrian Curran,Montserrat Laguno,Carl Fletcher,Jack Moody,Anton Pozniakon behalf of the NEAT-ID Foundation,and LAPTOP Study Team The Lancet Infectious Diseases. May 2026，Vol 26(5)：p510 24 Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study 在西班牙加利西亚婴儿中进行Nirsevimab普遍预防，对横跨两个呼吸道合胞病毒季节的医院和初级保健结果的影响（NIRSE-GAL）：一项基于人群的前瞻性观察研究 Josefina L Razzini,Iago Giné-Vázquez,Jing Jin,María-Isolina Santiago-Pérez,Olaia Pérez-Martínez,María-Teresa Otero-Barrós,Nuria Suárez-Gaiche,Rolf Kramer,Leticia Platero-Alonso,Rosa-María Álvarez-Gil,Olga-María Ces-Ozores,Victoria Nartallo-Penas,Susana Mirás-Carballal,Marta Piñeiro-Sotelo,Juan-Manuel González-Pérez,Carmen Rodríguez-Tenreiro-Sánchez,Ángela Manzanares-Casteleiro,Ana Dacosta-Urbieta,Cintia Álvarez-Smith,Irene Rivero-Calle,Antonio Salas,Carmen Durán-Parrondo,Narmeen Mallah,Federico Martinón-Torres The Lancet Infectious Diseases. May 2026，Vol 26(5)：p522 25 Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study CRS3123治疗成人艰难梭菌感染初次发作或首次复发的安全性和有效性：一项2期、随机、双盲、多中心、万古霉素对照研究 Thomas Louie,Wendy Ribble,Louis Boccumini,Katherine Johnson,Mary A De Groote,Joshua Day,Clifford Mason,Xicheng Sun,Jane Freeman,Kenan Gu,Glenn Tillotson,Mark H Wilcox,Nebojsa Janjic,Thale C Jarvis,Seema U Nayak,Urs A Ochsner,Jon B Bruss The Lancet Infectious Diseases. May 2026，Vol 26(5)：p535 REVIEW（综述） 26 The Emerging Resistance Index: tracking early resistance to new antibiotics 新兴耐药指数：追踪新抗生素的早期耐药性 Jacopo Garlasco,Fabiana Arieti,Matteo Morra,Maela Tebon,Diego Ortiz,Maria Diletta Pezzani,Karin Odoj,Federica Manco,Alessandro Cassini,Stephan Harbarth,Elisabeth Presterl,Biljana Carevic,Gunnar Kahlmeter,Karin Thursky,Paola Morelli,Stefan Hagel,Alessia Savoldi,Evelina Tacconelli The Lancet Infectious Diseases. May 2026，Vol 26(5)：e219 27 Kyasanur Forest disease: an emerging arboviral threat 基萨努尔森林病：一种新兴的虫媒病毒威胁 Neha Pandey,Sunit K Singh The Lancet Infectious Diseases. May 2026，Vol 26(5)：e228 PERSONAL VIEW（个人观点） 28 Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings 重新考虑高传播地区对缓慢消除抗疟药物耐药性的临床评估 Nicholas J White,James A Watson The Lancet Infectious Diseases. May 2026，Vol 26(5)：e240 GRAND ROUND（大查房） 29 Safe delivery of intensive care for Marburg virus disease in Rwanda 卢旺达安全实施马尔堡病毒病重症监护 Eric Seruyange,Ernest Nahayo,François Xavier Uwimana,Joseph Biramahire,Fidele Hakorimana,Menelas Nkeshimana,David Turatsinze,Anselme Bizimana,Hassan Mugabo,Bosco Burakari,Ryan P Westergaard,Louise Mwiseneza,Nicholas Niyigaba,Jean Pierre Sibomana,Tsion Firew,Lambert Ingabire,Gaston Nyirigira,Etienne Kayigi,Evariste Mushuru,Marie Grace Niwemuhoza,Marie Grace Niyonizeye,Gisele Isingizwe,Josué Bongwa Rwibutso,Jean Pierre Nzabana,Gentil Semahoro Ndayishimiye,Déo Kimalarungu Ntakambirwa,Serge Kazindu,Halifa Ndayisabye,Eric Remera,Leon Mutesa,Jean Paul Rwabihama,Muhammed Semakula,Robert Fowler,Ruggero Giuliani,Jacob Goldberg,Frederique Jacquerioz,Janet Diaz,Amanda Rojek,Claude M Mambo,Yvan Butera,Sabin Nsanzimana,Elizabeth O Moreton,Thomas E Fletcher,William A Fischer 2nd,Théogène Twagirumugabe The Lancet Infectious Diseases. May 2026，Vol 26(5)：e248 CLINICAL PICTURE（临床图像） 30 Disseminated fusariosis arising from onychomycosis in a haematopoietic transplant recipient 造血干细胞移植受者甲癣引发的播散性镰刀菌病 Wouter A A de Steenhuijsen Piters,Man Wai Tang,Inge A H van den Berk,M E Baarsma,Karin van Dijk The Lancet Infectious Diseases. May 2026，Vol 26(5)：e256 THE LANCET Infectious Diseases. Volume 26Number 6 柳叶刀·传染病学26卷 6期 https://www.thelancet.com/journals/laninf/issue/current Editorial（社论） 1 The value of infectious disease conferences 传染病会议的价值 The Lancet Infectious Diseases The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p549 Comment（述评） 2 From emergency to integration: research as the bridge in mpox control 从紧急应对到整合：作为猴痘防控的桥梁的研究 Yap Boum,Mosoka Fallah,Michel Muteba,Henry Kyobe Bosa,Kyeng Mercy,John Misaki Wayengera,Bruce Kirenga,John Otshudiema,Placide Mbala,Marie-Roseline Belizaire,Ngashi Ngongo,Jean Kaseya The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p550 3 Strength of ATLAS or lady luck in a sepsis management trial? 脓毒症治疗试验，是ATLAS的力量还是幸运女神的眷顾？ Mojdeh Azimi,Dick Menzies The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p552 4 Reimagining radical cure for Plasmodium vivax 重新构思间日疟原虫的根治方案 Pyae Linn Aung,Liwang Cui The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p554 5 Does BA.3.2 epidemiology imply a change in SARS-CoV-2 evolution? BA.3.2的流行病学是否意味着SARS-CoV-2进化方向的改变？ Lu Zhang,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p555 Correspondence（读者来信） 6 Concerns regarding study of spatial emanators for malaria control 关于研究用于疟疾防控的空间传播因子的担忧 John Bradley,Richard Hayes,Peter G Smith,Immo Kleinschmidt The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e209 7 Concerns regarding study of spatial emanators for malaria control – Authors' reply 关于疟疾防控中空间散发器研究的关切——作者回复 Richard James Allan,Chad L Cross,Louisa Alexandra Messenger The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e210 Newsdesk（新闻台） 8 Bangladesh launches measles vaccine drive amid outbreak 孟加拉国在疫情期间启动麻疹疫苗接种运动 Samaan Lateef The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e211 9 Tecovirimat no longer approved for mpox in the EU 欧盟不再批准替可韦利马用于猴痘治疗 Sanjeet Bagcchi The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e212 10 Highlights of ESCMID Global 2026 2026年ESCMID全球大会亮点 Syeda Saleha Hassan The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e213 11 Global vaccination drive reaches 18.3 million children 全球疫苗接种运动已覆盖1830万儿童 Timothy Jesudason The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e214 12 Israel accused of using “water as a weapon” in Gaza 以色列被指控在加沙"以水为武器" Talha Burki The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e215 13 Research in brief 研究简报 Priya Venkatesan The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e216 Obituary（讣告） 14 James Phillip Luby 詹姆斯·菲利普·卢比 Sanjeet Bagcchi The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p558 Profile（人物介绍） 15 Daniela Hozbor—raising the bar for pertussis vaccines 丹妮拉·霍兹博尔——提升百日咳疫苗标准 Tony Kirby The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p559 Media Watch（媒体观察） Book（书籍） 16 Building bridges 搭建桥梁 Hollie Sherwood-Martin The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p560 Articles（论著） 17 Safety of MVA-BN vaccine in health-care personnel in DR Congo: a prospective cohort study MVA-BN疫苗在刚果（金）医务人员中的安全性：前瞻性队列研究 Faisal S Minhaj,Anna Mandra,Béatrice U Nguete,Toutou Likafi,Gaston Kokola,Stephanie Tran,Jordan L Kennedy,Benjamin Monroe,Christine M Hughes,Taina Joseph,Marissa K Person,Michael B Townsend,Panayampalli S Satheshkumar,Joelle Kabamba,Mary G Reynolds,Agam K Rao,Dorah Kasongo,Patricia A Yu,Yon Yu,Robert Shongo Lushima,Didine Kaba,Brett Petersen,Andrea M McCollum The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p561 18 Immunogenicity and safety of MVA-BN vaccine administered 5 years after a two-dose primary series in DR Congo: a prospective cohort study 两剂基础免疫后5年接种MVA-BN疫苗的免疫原性和安全性：刚果（金）前瞻性队列研究 Lalita Priyamvada,Faisal S Minhaj,Toutou Likafi,Elisabeth Pukuta,Elisabeth Muyamuna,William C Carson,Margaret Moriarty,Sergio Rodriguez,Taina Joseph,Joelle Kabamba,Gaston Kokola,Robert Shongo Lushima,Jean-Jacques Muyembe-Tamfum,Christine M Hughes,Brett W Petersen,Yon Yu,Agam Rao,Andrea M McCollum,Didine K Kaba,Beatrice U Nguete,Panayampalli S Satheshkumar,Michael B Townsend The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p571 19 A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study 伊布分支疫情期间卢旺达猴痘感染诱导和疫苗诱导抗体联合ELISA检测：观察性横断面临床验证研究 Jenny Clarke,Herve Semukunzi,Sian E Faustini,Jennifer L J Heaney,Hin Fai Kwok,Jean Marie Vianney Uwimana,Karishma Gokani,Gilbert Rukundo,Jean Pierre Musabyimana,Prosper Ingabire,Leopold Bitunguhari,Jean de Dieu Harelimana,Alex G Richter,Claude M Muvunyi,Christopher A Greenand the MpoxCARE Study Team The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p581 20 Case presentation of patients hospitalised with mpox (subclade Ib/2023sh) including children, adolescents, and adults in South Kivu, Democratic Republic of the Congo: an observational cohort study 刚果（金）南基伍省住院猴痘患者（伊布亚分支/2023sh）病例报告，包括儿童、青少年和成人：观察性队列研究 Luis Flores Girón,Gustavo Sganzerla Martinez,Baganda Ntahuma Daniel,Alfred Kesheni Bisimwa,Nkonzi Pacific,Georges Assumani Martin,Jean Christian Amini Kabwana,Anuj Kumar,Ali Toloue Ostadgavahi,Mansi Dutt,Kawaya Lusante Bénite,Mangura Hamuli Damien,Christian Gortázar,Bahaa Abu-Raya,Alyson A Kelvin,Kaleme Kiswele Prince,David J Kelvin The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p590 21 Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2×2 factorial, superiority trial 坦桑尼亚和乌干达HIV相关脓毒症的即时或高剂量抗结核治疗（ATLAS）：一项3期、开放标签、随机对照、2×2析因、优效性试验 Scott K Heysell,Stellah G Mpagama,Edwin Nuwagira,Bibie Said,Mark Conaway,Megan Null,Tania A Thomas,David R Boulware,Eva Otoupalova,Rinah Arinaitwe,Rhina Mushagara,Louisa Edwards,Peter Buzaare,Athumani M Ngoma,Davis Muganzi,Geofrey Gidoi,Samuel Jjunju,Antony Gulinja,Arestaricky G Rimoy,Fredrick C Mwita,Jeremiah Kidola,Oscar Atwiine,David Ocaaki,Dalton K Munyambalu,Jie Liu,Lucas Ampaire,Buliga Mujaga,Prakruti Rao,Alphonce Liyoyo,Margaretha Sariko,Conrad Muzoora,Christopher C Moore The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p601 22 Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial 7天高剂量伯氨喹和单剂量他芬诺奎与14天低剂量伯氨喹治疗间日疟原虫疟疾的有效性和安全性（EFFORT）：一项多中心、开放标签、随机对照、优效性试验 Tamiru Shibiru Degaga,Ayodhia Pitaloka Pasaribu,Rupam Tripura,Najia Ghanchi,Megha Rajasekhar,Bipin Adhikari,Benedikt Ley,Samuel Alemu Bamboro,Fareeha Abdul Jabbar,Nurfadhilah Hasibuan,Tedla Teferi Tego,Shane Zehra,Bushra Qurashi,Hellen Mnjala,Grant Lee,Peixuan Li,Abdul Momin Kazi,Widaya Safitri,Yulita Yulita,Dedi Sahat Parningotan Siagian,Deni Syahputra,Halik Hadi,Taj Muhammad,Amna Ibrahim,Nasreen Syed,Khuda Dost,Agatha Mia Puspitrasari,Pinkan Pertiwi Kariodimedjo,Anjana Rai,Angela Rumaseb,Edwin Sutanto,Mom Ean,Asia Khan,Meas Sokha,Robert James Commons,Sophie Weston,Rintis Noviyanti,Tom Peto,James J Callery,Umair Ali,Tariq Mehmood,Arjen Dondorp,Angela Devine,Ery Setiawan,Muthoni Mwaura,Sarah Cassidy-Seyoum,Rodas Temesgen,Dagimawie Tadesse Abate,Eyerusalem Beyene Erjabo,Geremew Gashaw Gessa,Fitsum Getahun Kiros,Muhammad Imran Usmani,Ali Raza,Adugna Woyessa,Asrat Hailu,Julie A Simpson,Amalia Karahalios,Mohammad Asim Beg,Lorenz von Seidlein,Lek Dysoley,Sarah Auburn,Ric N Price,Kamala Thriemer The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p614 23 Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial ETVAX疫苗对冈比亚儿童产肠毒素大肠杆菌阳性腹泻的有效性：一项双盲、随机、安慰剂对照、2b期试验 M Jahangir Hossain,Fatou Secka,Lady C Sanyang,Raifu Taiwo,Emmanuel C Okoh,Olubunmi A Olubiyi,Mbemba Drammeh,Emmanuel U Richard,Ahmed D Balami,Mama Drammeh,Samba Juma Jallow,Bakary Sonko,Paticia Ezedimbu-Michael,Jacinta Obiaduo,Ousman Secka,Joanna Kaim,Björn Sjöstrand,Agneta Lissmats,Nils Carlin,Umberto D'Alessandro,Ann-Mari Svennerholm,Thomas F Wierzba The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p627 24 Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial 伤寒和副伤寒A沙门氏菌结合疫苗候选物在欧洲健康成人中的安全性和免疫原性：1期随机对照试验 Ilse De Coster,Mohammad AbdelGhany,Eleanna Sarakinou,Chiara Fineschi,Elisa Marchetti,Rita La Gaetana,Simona Nigro,Martina Carducci,Luisa Massai,Valentino Conti,Omar Rossi,Giulia Luna Cilio,Alimamy Serry-Bangura,Pietro Tessitore,Pierre Van Damme,Kanchanamala Withanage,Francesca Micoli,Francesco Berlanda Scorza,Simona Rondini,Usman N Nakakana,Ashwani Kumar Arora The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p638 Review（综述） 25 British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update 英国医学真菌学会严重真菌病诊断最佳实践建议：2025年更新 Silke Schelenz,Alireza Abdolrasouli,Darius Armstrong-James,H Ruth Ashbee,Richard Barton,Tihana Bicanic,Andy Borman,Lottie Brown,Chris Eades,Laura Ferreras-Antolin,Rebecca Gorton,Ronan McMullan,Iain Page,Nelun Perera,Riina Rautemaa-Richardson,Johannes Wagener,P Lewis White,David W Denning The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e217 26 Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia 血液系统恶性肿瘤或造血干细胞移植后发热性中性粒细胞减少患者的经验性和目标性抗菌治疗：第10届欧洲白血病感染会议建议 Dina Averbuch,Yuri Vanbiervliet,Francesco Baccelli,Malgorzata Mikulska,Dionysios Neofytos,Carolina Garcia-Vidal,Manuela Aguilar-Guisado,Nicole Blijlevens,Patricia Munoz,Catherine Cordonnier,Murat Akova,Thierry Calandra The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e232 Personal View（个人观点） 27 Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development 结核病治疗的未来保障：药物与耐药性检测协同开发框架 Francesca Saluzzo,Seda Yerlikaya,Susan Elizabeth Dorman,Kathleen Eisenach,Maha Reda Farhat,Nazir Ismail,Christian Lienhardt,Timothy M Walker,Fatima Jones,Ana Yepes,Adam Penn-Nicholson,Morten Ruhwald,Bavesh Kana,Claudia Maria Denkinger,Daniela Maria Cirillo The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e248 Grand Round（大查房） 28 Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer 糖尿病足溃疡中多重耐药嗜麦芽窄食单胞菌骨髓炎致膝下截肢 Alejandro Arbona-Lampaya,Ricardo A Pérez-Ojeda,Melanie Santos-Marrero,Adrián Pérez-Aybar The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e257 Clinical Picture（临床图像） 29 Severe inguinal bubo and haemorrhagic exanthem in autochthonous clade Ib mpox 本土伊布分支猴痘导致的严重腹股沟淋巴结肿大和出血性皮疹 Patrick E Obermeier,Philipp Schulz,Hartmut Stocker,Ingo Ochlast,Livia Schrick,Annika Brinkmann,Pascal Migaud The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e266

2026-05-31

·北京医学感染与传染研究

柳叶刀传染病学 26卷 1-6期（2026年5月30日更新）

THE LANCET Infectious Diseases. Volume 26Number 1 柳叶刀传染病学 26卷 1期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Urgent need for infection prevention and control in prisons 监狱中感染预防和控制的迫切需求 The Lancet Infectious Diseases The Lancet Infectious Diseases Vol 26(1):p1 COMMENT（述评） 2 Now is the time to integrate serology into routine infectious disease surveillance 现在是时候将血清学纳入常规传染病监测了 Simon Cauchemez The Lancet Infectious Diseases Vol 26(1):p2 3 Reassessing sotrovimab's role in COVID-19: insights and implications 重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示 Daniele Focosi,Fabrizio Maggi The Lancet Infectious Diseases Vol 26(1):p3 4 Shaping opportunities for future clinical trials in tuberculosis 为未来结核病临床试验创造机会 Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich The Lancet Infectious Diseases Vol 26(1):p5 5 Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda 乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化 Arjen M Dondorp The Lancet Infectious Diseases Vol 26(1):p6 6 A safe start for PfSPZ Vaccine, but efficacy in children remains elusive PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸 Nicholas Aderinto,Temitomi Jane Oyedele The Lancet Infectious Diseases Vol 26(1):p8 7 Rifasutenizol-based triple therapy for Helicobacter pylori infection 以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染 Jinnan Chen,Hong Lu The Lancet Infectious Diseases Vol 26(1):p9 8 The smallest faith 最渺小的信念 Steven A Pergam The Lancet Infectious Diseases Vol 26(1):p11 9 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease 新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标 Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson The Lancet Infectious Diseases Vol 26(1):p13 10 Strengthening global preparedness and response to arboviral disease threats: a call to action 加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁 WHO Global Arbovirus Initiative Technical Advisory Group 世界卫生组织全球虫媒病毒倡议技术咨询小组 The Lancet Infectious Diseases Vol 26(1):p15 11 Introducing our cover artist for 2026: Daria Lada 介绍我们2026年的封面艺术家：达里亚·拉达 Marco De Ambrogi The Lancet Infectious Diseases Vol 26(1):p17 Correspondence（读者来信） 12 Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2 新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况 Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases Vol 26(1):e1 13 Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响 Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens The Lancet Infectious Diseases Vol 26(1):e3 14 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致 Nader Ebrahimi,Amir Ghaemi The Lancet Infectious Diseases Vol 26(1):e6 15 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复 Frank Aarestrup,Marion Koopmans The Lancet Infectious Diseases Vol 26(1):e7 16 Time to tackle vaccine–HLA associations with artificial intelligence 是时候用人工智能解决疫苗-人类白细胞抗原关联问题了 Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington The Lancet Infectious Diseases Vol 26(1):e8 Corrections（更正） 17 Correction to Lancet Infect Dis 2025; published online Oct 29. 《柳叶刀-传染病》2025年更正；在线发表于10月29日 https://doi.org/10.1016/S1473-3099(25)00466-9 The Lancet Infectious Diseases Vol 26(1):e9 18 Correction to Lancet Infect Dis 2025; published online Oct 27. 《柳叶刀-传染病》2025年更正；在线发表于10月27日 https://doi.org/10.1016/S1473-3099(25)00546-8 The Lancet Infectious Diseases Vol 26(1):e9 19 Correction to Lancet Infect Dis 2025; 25: 1084–96 《柳叶刀-传染病》2025年更正；25卷：1084-1096页 The Lancet Infectious Diseases Vol 26(1):e9 20 Correction to Lancet Infect Dis 2025; published online Nov 10. 《柳叶刀-传染病》2025年更正；在线发表于11月10日 https://doi.org/10.1016/S1473-3099(25)00550-X The Lancet Infectious Diseases Vol 26(1):e9 Newsdesk（新闻台） 21 Highlights of IDWeek 2025 2025年IDWeek亮点 Phoebe Hall The Lancet Infectious Diseases Vol 26(1):e10 22 WHO publishes update on global antibiotic resistance 世界卫生组织发布全球抗生素耐药性最新情况 Timothy Jesudason The Lancet Infectious Diseases Vol 26(1):e11 23 European Commission to fund new medicines for dengue 欧盟委员会资助登革热新药研发 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):e12 24 Second report from the UK Covid-19 Inquiry 英国新冠肺炎调查第二次报告 Talha Burki The Lancet Infectious Diseases Vol 26(1):e13 25 Infectious disease surveillance update 传染病监测最新情况 Cahal McQuillan The Lancet Infectious Diseases Vol 26(1):e14 26 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases Vol 26(1):e15 Obituary（讣告） 27 Jean Louis Abdourahim Ndiaye 让·路易斯·阿卜杜拉希姆·恩迪亚耶 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):p19 Profile（人物介绍） 28 Fortunate Machingura—tackling climate change and disease 福图纳特·马辛古拉——应对气候变化与疾病 Tony Kirby The Lancet Infectious Diseases Vol 26(1):p20 Media Watch（媒体观察） Book（书籍） 29 The social and political drivers behind pandemics 大流行背后的社会和政治驱动因素 Emma Louise Fabiani The Lancet Infectious Diseases Vol 26(1):p21 Articles（论著） 30 Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究 Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek The Lancet Infectious Diseases Vol 26(1):p22 31 Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验 RECOVERY Collaborative Group RECOVERY协作组 The Lancet Infectious Diseases Vol 26(1):p34 32 A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验 John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team The Lancet Infectious Diseases Vol 26(1):p46 33 Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析 Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar The Lancet Infectious Diseases Vol 26(1):p55 34 Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验 Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka The Lancet Infectious Diseases Vol 26(1):p67 35 Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验 Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller The Lancet Infectious Diseases Vol 26(1):p79 36 Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究 Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda The Lancet Infectious Diseases Vol 26(1):p91 37 Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验 Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group The Lancet Infectious Diseases Vol 26(1):p101 Series（专题研讨会） 38 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Innovation in active and passive immunisation of people who are immunocompromised: a call to action 免疫功能低下人群主动和被动免疫接种的创新：行动呼吁 Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa The Lancet Infectious Diseases Vol 26(1):e16 39 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship 应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理 Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo The Lancet Infectious Diseases Vol 26(1):e30 Review（综述） 40 Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project 揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述 Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro The Lancet Infectious Diseases Vol 26(1):e49 Personal View（个人观点） 41 Azithromycin mass drug administration: balancing survival benefits and risks in children 阿奇霉素大规模药物给药：平衡儿童生存益处与风险 Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro The Lancet Infectious Diseases Vol 26(1):e62 Clinical Picture（临床影像） 42 Unexpected finding in a 17-year-old female undergoing screening colonoscopy 17岁女性接受筛查结肠镜检查时的意外发现 Ziheng Calvin Xu,Ethan Tan,Mayur Garg The Lancet Infectious Diseases Vol 26(1):e75 THE LANCET Infectious Diseases. Volume 26Number 2 柳叶刀传染病学 26卷 2期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Call for letters 征稿启事 The Lancet Infectious Diseases The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111 Comment（述评） 2 Long COVID is here to stay—even in children 长期新冠症状将持续存在——即使在儿童中亦是如此 Danilo Buonsenso The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112 3 Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment 利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用 Ming Hong Choi,Ivan Fan Ngai Hung The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113 4 A new monoclonal in the arMAMentarium against malaria 抗疟“武器库”中的新型单克隆抗体 Freia-Raphaella Lorenz,Matthew B B McCall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115 5 Household transmission of mpox in Africa: limited in adults but more prevalent in children 非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍 Oriol Mitjà,Michael Marks The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117 6 The lasting lessons of mpox: infection, vaccination, and immune memory 猴痘带来的持久教训：感染、疫苗接种和免疫记忆 Raianna Fantin,Camila H Coelho The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118 7 Xpert-Ultra for diagnosing asymptomatic tuberculosis Xpert-Ultra用于诊断无症状结核病 Xia Yu,Hairong Huang The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120 8 The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action 基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动 David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122 Correspondence（读者来信） 9 Spillover in dengue trials 登革热试验中的溢出效应 Thomas A Smith,Samuel I Watson The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77 10 Spillover in dengue trials – Author's reply 登革热试验中的溢出效应——作者回复 Fernando Abad-Franch The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78 11 Updating the traditional voriconazole trough concentration range 传统的伏立康唑谷浓度范围更新 Rongqiang Liao,Xiaoyuan Zheng The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79 12 Updating the traditional voriconazole trough concentration range – Authors' reply 传统的伏立康唑谷浓度范围更新——作者回复 Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80 13 Clinical course and neurological profile of Kyasanur Forest disease 基萨努尔森林病的临床病程和神经特征 Nitin Gupta,Tirlangi Praveen Kumar The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82 Corrections（更正） 14 Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7 对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 15 Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4 对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 Newsdesk（新闻台） 16 Promising early data for sorfequiline 索氟维林早期数据令人鼓舞 Ed Holt The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84 17 Highlights from ASTMH 2025 2025年美国热带医学与卫生学会年会亮点 Marco De Ambrogi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85 18 Brazil approves domestic single-shot dengue vaccine 巴西批准国产单剂登革热疫苗 Marcia Triunfol The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86 19 CDC cuts to childhood vaccine recommendations 美国疾控中心削减儿童疫苗接种建议 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87 20 WHO launches unified plan for coronaviruses 世界卫生组织启动冠状病毒统一计划 Talha Burki The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88 21 Infectious disease surveillance update 传染病监测更新 Cahal McQuillan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89 22 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90 Obituary（讣告） 23 Walter Dowdle 沃尔特·道德尔 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124 Profile（人物简介） 24 Katie Anders—improving global dengue control 凯蒂·安德斯——改善全球登革热防控 Tony Kirby The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125 Media Watch（媒体观察） Film（电影） 25 Eliminating Guinea worm 根除麦地那龙线虫 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126 Articles（论著） 26 Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study 奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127 27 Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial 口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验 William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139 28 Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial 头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验 David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148 29 Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验 single-blind, randomised, controlled, dose-ranging, phase 2 trial Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160 30 Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial 人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验 Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170 31 Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study 布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究 Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182 32 Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study 比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究 Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190 33 Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study 乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究 Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203 Review（综述） 34 Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge 侵袭性A组链球菌感染：从2022-23年激增中吸取的教训 Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91 35 A clinical practice guideline for tuberculous meningitis 结核性脑膜炎临床实践指南 Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96 36 Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults 缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症 Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112 Personal View（个人观点） 37 A transformation in cholera surveillance 霍乱监测的变革 Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124 Clinical Picture（临床图像） 38 Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing 尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展 Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130 THE LANCET Infectious Diseases. Volume 26Number 3 柳叶刀传染病学 26卷 3期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL（社论） 1 Promises and challenges of AI in infectious diseases 人工智能在传染病领域的承诺与挑战 The Lancet Infectious Diseases The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213 COMMENT（述评） 2 More real-world evidence for RSV vaccines in the global community 全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据 Kristina L Bajema,Wesley H Self The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214 3 Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet 猴痘快速诊断抗原检测及分散检测的必要性——尚待完善 Daniel Mukadi-Bamuleka,Kevin K Ariën The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215 4 Solving the data bottleneck for artificial intelligence in infectious diseases 解决传染病人工智能领域的数据瓶颈问题 Cesar de la Fuente-Nunez The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217 5 Artificial intelligence and One Health: potential for spillover prediction? 人工智能与“同一健康”理念：能否预测病原体外溢？ Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219 6 Artificial intelligence in the development of vaccines for infectious diseases 人工智能在传染病疫苗研发中的应用 Steve Black,Shabir A Madhi,Rino Rappuoli The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221 7 Peer review at The Lancet Infectious Diseases in 2025 2025年《柳叶刀-传染病学》期刊专家评审 Ursula Hofer The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223 8 Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025 感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家 The Lancet Infectious Diseases Editors The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132 CORRESPONDENCE（读者来信） 9 Methodological considerations in the attribution of long COVID to first or second infection 首次或二次感染导致长期新冠症状的方法学考量 Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139 10 Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply 首次或二次感染导致长期新冠症状的方法学考量——作者回复 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141 11 Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答 Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142 12 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者 Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144 13 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复 David L Paterson,Abdullah T Aslan,Patrick N A Harris The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145 CORRECTIONS（更正） 14 Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0 《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0 The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 15 Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X 《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 NEWSDESK（新闻台） 16 Rabies an increasing threat in Ukraine 乌克兰狂犬病威胁日益加剧 Ed Holt The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147 17 People needing trachoma interventions at record low 需要沙眼干预措施的人数创历史新低 Timothy Jesudason The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148 18 Uneven STI response in EU/EEA countries 欧盟/欧洲经济区国家性传播感染应对措施不均衡 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149 19 Controversial HBV vaccine trial in Guinea-Bissau halted 几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停 Talha Burki The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150 20 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151 OBITUARY（讣告） 21 Ivan Hirsch 伊万·赫希 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224 PROFILE（人物介绍） 22 Reem Abu Shomar— championing water safety in Gaza 里姆·阿布·舒马尔——加沙地带水安全倡导者 Tony Kirby The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225 MEDIA WATCH（媒体观察） Book（书籍） 23 A prescription for public health literacy 提升公众健康素养的良方 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226 Book（书籍） 24 Imagining the inevitable 想象不可避免之事 Cahal McQuillan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227 Film（电影） 25 Women's autonomy, safe sex and HIV prevention 女性自主权、安全性行为与艾滋病预防 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228 ARTICLES（论著） 26 Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study 英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究 Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229 27 Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial 印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验 Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239 28 Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial 血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析 Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250 29 Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study 刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究 Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260 30 Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis 伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析 Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270 31 Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析 GBD 2023 Chagas Disease and RAISE Study Collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284 32 Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial 乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验 Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302 33 Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial 美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验 Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314 SERIES（研讨会） Artificial Intelligence and Infectious Diseases 人工智能与传染病 34 Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice 人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架 Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152 35 Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives 人工智能与传染病诊断：现状与未来展望 Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168 36 Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery 人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现 Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181 REVIEW（综述） 37 Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia 血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议 Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193 CLINICAL PICTURE（临床图像） 38 Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection 人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染 Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B Spiller,Baharak Afshar The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207 THE LANCET Infectious Diseases. Volume 26Number 4 柳叶刀传染病学 26卷 4期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 GoGoVax dispels hopes for gonorrhoea vaccination GoGoVax让淋病疫苗的希望破灭 The Lancet Infectious Diseases The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329 COMMENT（述评） 2 Do the benefits of universal screening outweigh the harms? 全民筛查的益处是否大于害处？ Alanna N Gillespie,Emma Webb,Valerie Sung The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330 3 Chikungunya in Brazil: vaccination strategies informed by mathematical modelling 巴西基孔肯雅热：基于数学建模的疫苗接种策略 José Lourenço,Marta Giovanetti The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331 4 Chikungunya adolescent vaccination and the distinct risk–benefit landscapes 青少年接种基孔肯雅热疫苗及独特的风险-获益情况 Ernesto T A Marques,Simon Barratt-Boyes The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333 5 Circulation of clade Ib mpox outside of Africa—are we prepared? 非洲以外地区Ib分支猴痘的传播——我们准备好了吗？ Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334 6 I worked at WHO: the USA leaving will not make America healthier 我曾在世卫组织工作：美国退出不会让美国更健康 Krutika Kuppalli The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336 CORRESPONDENCE（读者来信） 7 Maternal views on RSV vaccination in the UK's second season 英国第二季呼吸道合胞病毒疫苗接种的产妇观点 Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209 8 Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters 利用COVID-19 LP.8.1 mRNA加强针克服免疫印记 Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212 CORRECTIONS（更正） 9 Correction to Lancet Infect Dis 2025; published online Nov 27. https://doi.org/10.1016/S1473-3099(25)00605-X 《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 10 Correction to Lancet Infect Dis 2026; 26: 343–61 《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 11 Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3 《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 12 Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9 《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 NEWSDESK（新闻台） 13 UK loses measles elimination status as cases rise 随着病例增加，英国失去麻疹消除地位 Priya Venkatesan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215 14 Brazil launches implementation study of lenacapavir 巴西启动来那卡帕韦实施研究 Tony Kirby The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216 15 Clade Ib mpox in southwest Indian Ocean islands 西南印度洋岛屿出现Ib分支猴痘 Esther Nakkazi The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217 16 EMA approves combined COVID-19 and flu mRNA vaccine 欧洲药品管理局批准COVID-19和流感联合mRNA疫苗 Talha Burki The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218 17 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219 OBITUARY（讣告） 18 Nicholas John White 尼古拉斯·约翰·怀特 Sanjeet Bagcchi The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339 PROFILE（人物简介） 19 Katharina Kranzer—led by curiosity, committed to capacity 卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力 Tony Kirby The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340 MEDIA WATCH（媒体观察） Film（电影） 20 Leishmaniasis: a story of two continents 利什曼病：两个大陆的故事 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341 Book（书籍） 21 Finding your voice in a world of uncertainty 在不确定的世界中找到自己的声音 Carrie Fielden The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342 ARTICLES（论著） 22 Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析 GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators GBD 2023下呼吸道感染和抗菌素耐药性协作组 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343 23 Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis 英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析 Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362 24 Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study 法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究 Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374 25 Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study 以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究 Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384 26 Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study 使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究 Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394 27 The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study 巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究 Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406 28 Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil 青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果 Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417 29 National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study 孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究 Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429 REVIEW（综述） 30 Autoantibodies in long COVID: a systematic review 长新冠中的自身抗体：一项系统综述 Fabian Wilhelm,Janne Cadamuro,Sylvia Mink The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220 31 Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE) 登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE） Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231 PERSONAL VIEW（个人观点） 32 Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali 通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解 Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245 GRAND ROUND（大查房） 33 Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned 儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训 Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259 CLINICAL PICTURE（临床图像） 34 Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis 肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎 Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268 THE LANCET Infectious Diseases. Volume 26Number 5 柳叶刀·传染病学26卷 5期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 How are vaccine recommendations made? 疫苗建议是如何制定的？ The Lancet Infectious Diseases The Lancet Infectious Diseases. May 2026，Vol 26(5)：p439 COMMENT（述评） 2 First efficacy evidence for a multistage malaria vaccine targeting infection and transmission 针对感染和传播多阶段的疟疾疫苗首次显示出有效性证据 Gemma Moncunill,Carlota Dobaño The Lancet Infectious Diseases. May 2026，Vol 26(5)：p440 3 Lassa viral dynamics: implications for missed diagnosis 拉沙病毒动态：对漏诊的影响 Chinwe Lucia Ochu,William Douglas Evans The Lancet Infectious Diseases. May 2026，Vol 26(5)：p441 4 Nirsevimab over two RSV seasons: do the findings align with expectations? 两个呼吸道合胞病毒（RSV）季节中Nirsevimab的应用情况：研究结果是否符合预期？ Corinne Levy,Robert Cohen The Lancet Infectious Diseases. May 2026，Vol 26(5)：p443 5 Improving antimalarial therapeutic efficacy studies 提高抗疟治疗疗效研究的质量 Philip J Rosenthal The Lancet Infectious Diseases. May 2026，Vol 26(5)：p444 6 The case for routine patient review in long COVID research 在长期新冠研究中开展常规患者评估的理由 Letícia Soares,C H Romatowski,Gina Assaf,Chloé de Canson The Lancet Infectious Diseases. May 2026，Vol 26(5)：p446 CORRESPONDENCE（读者来信） 7 When mpox is not mpox: varicella and measles in DR Congo 当猴痘并非猴痘时：刚果民主共和国的水痘和麻疹病例 Levi Bugwaja,Nathan Banzi,Trust Faraja Mukika,Patrick Kazuba Bugale,Patrick Musole Bugeme,Emmanuel Biragi Nzenze,Heshima Lajeri Nzirimo,Salomon Mashupe Shangula,Justin Bengehya,Willy Kasi,Krutika Kuppalli,Camille Escadafal,Daniel Mukadi-Bamuleka,Jackie Knee,Jules Jackson,Elizabeth C Lee,Andrew S Azman,Espoir Bwenge Malembaka The Lancet Infectious Diseases. May 2026，Vol 26(5)：e209 8 Mpox virus in human breastmilk and tecovirimat pharmacokinetics: implications for postnatal transmission 人乳中的猴痘病毒及特考韦瑞药代动力学：对产后传播的影响 Francesca Colavita,Massimo Tempestilli,Silvia Meschi,Carla Pittini,Martina Rueca,Giuseppe Sberna,Fabrizio Carletti,Simone Lanini,Silvia Cammisa,Giulia Paviotti,Lorenza Driul,Miriam De Vito,Cesare Ernesto Maria Gruber,Marco Cotrufo,Eleonora Cimini,Valentina Mazzotta,Andrea Antinori,Carlo Tascini,Fabrizio Maggi,Licia Bordi The Lancet Infectious Diseases. May 2026，Vol 26(5)：e211 CORRECTIONS（更正） 9 Correction to Lancet Infect Dis 2026; 26: 522–34 对《柳叶刀-传染病》2026年第26卷第522–34页的更正 The Lancet Infectious Diseases. May 2026，Vol 26(5)：e213 NEWSDESK（新闻台） 10 New WHO recommendations for tuberculosis diagnosis 世卫组织新的结核病诊断建议 Timothy Jesudason The Lancet Infectious Diseases. May 2026，Vol 26(5)：e214 11 New report assesses antimicrobial pipeline 新报告评估抗菌药物研发管线 Manjulika Das The Lancet Infectious Diseases. May 2026，Vol 26(5)：e215 12 Meningitis B outbreak in England 英格兰B型脑膜炎暴发 Tony Kirby The Lancet Infectious Diseases. May 2026，Vol 26(5)：e216 13 WHO reports on health of migrants and refugees 世卫组织发布移民和难民健康报告 Talha Burki The Lancet Infectious Diseases. May 2026，Vol 26(5)：e217 14 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. May 2026，Vol 26(5)：e218 OBITUARY（讣告） 15 Christian C Patrick 克里斯蒂安·C·帕特里克 Sanjeet Bagcchi The Lancet Infectious Diseases. May 2026，Vol 26(5)：p448 PROFILE（人物简介） 16 Eizo Takashima—developing a new class of malaria vaccines 高石荣三——开发新型疟疾疫苗 Tony Kirby The Lancet Infectious Diseases. May 2026，Vol 26(5)：p449 MEDIA WATCH（媒体观察） Book（书籍） 17 Feminism and the AIDS epidemic 女权主义与艾滋病流行 Charlotte Day The Lancet Infectious Diseases. May 2026，Vol 26(5)：p450 ARTICLES（论著） 18 Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection study ProC6C-AlOH/Matrix-M预防恶性疟原虫感染和蚊子传播的有效性：一项2期随机对照人体疟疾感染研究 Mamady Kone,Jordan Plieskatt,Moussa Thienta,Bourama Kamate,Ebenezer A Ofori,Markus Gmeiner,Bayaya Haidara,Moussa B Kanoute,Bakary Traore,Ousmane A Poudiouguo,Hawa S Bayogo,Ibrahim Diarra,Karim Bengaly,Amatigue Zeguime,Daman Sylla,Adama Sacko,Stephen L Hoffman,Matthew B B McCall,Michael Theisen,Issaka Sagaraon behalf of the ProC6C Study Group The Lancet Infectious Diseases. May 2026，Vol 26(5)：p451 19 The effectiveness of long-lasting spatial repellent emanators against malaria in humanitarian crisis settings in northern Nigeria: a two-arm pragmatic, open-label, controlled trial 长效空间驱蚊剂在尼日利亚北部人道主义危机环境中预防疟疾的有效性：一项双臂实用、开放标签、对照试验 Richard James Allan,Ramona Scherrer,Sara Estecha-Querol,David Weetman,Laura Paris,Umar Ba'abba Goni,Fatima Idris Abdulhamid,Blaise Nfornuh Alenwi,Sajjad Ahmad,Chad L Cross,Garba Mohammed Ashir,Mala Waziri,Godwin Ntadom,Louisa Alexandra Messenger The Lancet Infectious Diseases. May 2026，Vol 26(5)：p464 20 Lassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia 拉沙热症状、病毒动态和宿主免疫反应（PREPARE）：利比里亚一项前瞻性观察队列研究 David A Wohl,Carwolo Pewu,Chanhwa Lee,Emmanuel Kerkula,Martha Gayflowu,Nukal Doetein,Katie R Mollan,Taylor J Krajewski,Becky Straub,Alfred Flomo,Amara Fofana,Stanley Kerkula,Thomas Sumo,Alexander Sampson,Samuel Vouh,Fred Flomo,McKenzie A Colt,Thomas Remont,Eleanor Rose Watts,Marta Zizek,Catherine Nimely,Minnie Ricks,Jefferson Sibley,William A Fischer II The Lancet Infectious Diseases. May 2026，Vol 26(5)：p475 21 Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study B群链球菌疫苗（GBS-AlpN）在孕妇及其婴儿中的免疫原性和安全性：一项2期、多中心、观察者设盲、随机、安慰剂对照研究 Paul T Heath,Ntokozo Zuma-Gwala,Rikke Bek Helmig,Elizea Horne,Anette Kjærbye-Thygesen,Mie Korslund Wiinblad Crusell,Maphoshane Nchabeleng,Renate Strehlau,Mohammed R Khalil,Christine E Jones,Jorne Biccler,Jeannett Dimsits,Bengt Johansson-Lindbom,Per B Fischer,Lidia Oostvogels,Shabir A Madhion behalf of the MVX0004 study group The Lancet Infectious Diseases. May 2026，Vol 26(5)：p486 22 Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial 单剂量口服减毒霍乱活疫苗PanChol的安全性和免疫原性：一项1a期、双盲、随机、安慰剂对照试验结果 Deborah R Leitner,Stephen R Walsh,Masataka Suzuki,Michaël Desjardins,Alisse Hannaford,Amy C Sherman,Hannah Levine,Lena Carr,Elliot Hammerness,Akina Osaki,Emily Sullivan,Bryan Wang,George I Balazs,Jun Bai Park Chang,Damien M Slater,Nirajan Puri,Carole J Kuehl,Wilbur H Chen,Jason B Harris,Steven Piantadosi,Lindsey R Baden,Matthew K Waldoron behalf of the PanChol study group The Lancet Infectious Diseases. May 2026，Vol 26(5)：p497 23 Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial 晚期艾滋病患者使用整合酶抑制剂与蛋白酶抑制剂治疗（LAPTOP）：一项多国、随机、开放标签、非劣效性试验 Georg M N Behrens,Lambert Assoumou,Geoffroy Liegeon,Andrea Antinori,Rafael Micán,Francesco G Genderini,Frank A Post,Jürgen K Rockstroh,Lisa Hamzah,Pere Domingo,Adrian Curran,Montserrat Laguno,Carl Fletcher,Jack Moody,Anton Pozniakon behalf of the NEAT-ID Foundation,and LAPTOP Study Team The Lancet Infectious Diseases. May 2026，Vol 26(5)：p510 24 Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study 在西班牙加利西亚婴儿中进行Nirsevimab普遍预防，对横跨两个呼吸道合胞病毒季节的医院和初级保健结果的影响（NIRSE-GAL）：一项基于人群的前瞻性观察研究 Josefina L Razzini,Iago Giné-Vázquez,Jing Jin,María-Isolina Santiago-Pérez,Olaia Pérez-Martínez,María-Teresa Otero-Barrós,Nuria Suárez-Gaiche,Rolf Kramer,Leticia Platero-Alonso,Rosa-María Álvarez-Gil,Olga-María Ces-Ozores,Victoria Nartallo-Penas,Susana Mirás-Carballal,Marta Piñeiro-Sotelo,Juan-Manuel González-Pérez,Carmen Rodríguez-Tenreiro-Sánchez,Ángela Manzanares-Casteleiro,Ana Dacosta-Urbieta,Cintia Álvarez-Smith,Irene Rivero-Calle,Antonio Salas,Carmen Durán-Parrondo,Narmeen Mallah,Federico Martinón-Torres The Lancet Infectious Diseases. May 2026，Vol 26(5)：p522 25 Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study CRS3123治疗成人艰难梭菌感染初次发作或首次复发的安全性和有效性：一项2期、随机、双盲、多中心、万古霉素对照研究 Thomas Louie,Wendy Ribble,Louis Boccumini,Katherine Johnson,Mary A De Groote,Joshua Day,Clifford Mason,Xicheng Sun,Jane Freeman,Kenan Gu,Glenn Tillotson,Mark H Wilcox,Nebojsa Janjic,Thale C Jarvis,Seema U Nayak,Urs A Ochsner,Jon B Bruss The Lancet Infectious Diseases. May 2026，Vol 26(5)：p535 REVIEW（综述） 26 The Emerging Resistance Index: tracking early resistance to new antibiotics 新兴耐药指数：追踪新抗生素的早期耐药性 Jacopo Garlasco,Fabiana Arieti,Matteo Morra,Maela Tebon,Diego Ortiz,Maria Diletta Pezzani,Karin Odoj,Federica Manco,Alessandro Cassini,Stephan Harbarth,Elisabeth Presterl,Biljana Carevic,Gunnar Kahlmeter,Karin Thursky,Paola Morelli,Stefan Hagel,Alessia Savoldi,Evelina Tacconelli The Lancet Infectious Diseases. May 2026，Vol 26(5)：e219 27 Kyasanur Forest disease: an emerging arboviral threat 基萨努尔森林病：一种新兴的虫媒病毒威胁 Neha Pandey,Sunit K Singh The Lancet Infectious Diseases. May 2026，Vol 26(5)：e228 PERSONAL VIEW（个人观点） 28 Reconsidering the clinical assessment of resistance to slowly eliminated antimalarial drugs in high-transmission settings 重新考虑高传播地区对缓慢消除抗疟药物耐药性的临床评估 Nicholas J White,James A Watson The Lancet Infectious Diseases. May 2026，Vol 26(5)：e240 GRAND ROUND（大查房） 29 Safe delivery of intensive care for Marburg virus disease in Rwanda 卢旺达安全实施马尔堡病毒病重症监护 Eric Seruyange,Ernest Nahayo,François Xavier Uwimana,Joseph Biramahire,Fidele Hakorimana,Menelas Nkeshimana,David Turatsinze,Anselme Bizimana,Hassan Mugabo,Bosco Burakari,Ryan P Westergaard,Louise Mwiseneza,Nicholas Niyigaba,Jean Pierre Sibomana,Tsion Firew,Lambert Ingabire,Gaston Nyirigira,Etienne Kayigi,Evariste Mushuru,Marie Grace Niwemuhoza,Marie Grace Niyonizeye,Gisele Isingizwe,Josué Bongwa Rwibutso,Jean Pierre Nzabana,Gentil Semahoro Ndayishimiye,Déo Kimalarungu Ntakambirwa,Serge Kazindu,Halifa Ndayisabye,Eric Remera,Leon Mutesa,Jean Paul Rwabihama,Muhammed Semakula,Robert Fowler,Ruggero Giuliani,Jacob Goldberg,Frederique Jacquerioz,Janet Diaz,Amanda Rojek,Claude M Mambo,Yvan Butera,Sabin Nsanzimana,Elizabeth O Moreton,Thomas E Fletcher,William A Fischer 2nd,Théogène Twagirumugabe The Lancet Infectious Diseases. May 2026，Vol 26(5)：e248 CLINICAL PICTURE（临床图像） 30 Disseminated fusariosis arising from onychomycosis in a haematopoietic transplant recipient 造血干细胞移植受者甲癣引发的播散性镰刀菌病 Wouter A A de Steenhuijsen Piters,Man Wai Tang,Inge A H van den Berk,M E Baarsma,Karin van Dijk The Lancet Infectious Diseases. May 2026，Vol 26(5)：e256 THE LANCET Infectious Diseases. Volume 26Number 6 柳叶刀·传染病学26卷 6期 https://www.thelancet.com/journals/laninf/issue/current Editorial（社论） 1 The value of infectious disease conferences 传染病会议的价值 The Lancet Infectious Diseases The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p549 Comment（述评） 2 From emergency to integration: research as the bridge in mpox control 从紧急应对到整合：作为猴痘防控的桥梁的研究 Yap Boum,Mosoka Fallah,Michel Muteba,Henry Kyobe Bosa,Kyeng Mercy,John Misaki Wayengera,Bruce Kirenga,John Otshudiema,Placide Mbala,Marie-Roseline Belizaire,Ngashi Ngongo,Jean Kaseya The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p550 3 Strength of ATLAS or lady luck in a sepsis management trial? 脓毒症治疗试验，是ATLAS的力量还是幸运女神的眷顾？ Mojdeh Azimi,Dick Menzies The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p552 4 Reimagining radical cure for Plasmodium vivax 重新构思间日疟原虫的根治方案 Pyae Linn Aung,Liwang Cui The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p554 5 Does BA.3.2 epidemiology imply a change in SARS-CoV-2 evolution? BA.3.2的流行病学是否意味着SARS-CoV-2进化方向的改变？ Lu Zhang,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p555 Correspondence（读者来信） 6 Concerns regarding study of spatial emanators for malaria control 关于研究用于疟疾防控的空间传播因子的担忧 John Bradley,Richard Hayes,Peter G Smith,Immo Kleinschmidt The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e209 7 Concerns regarding study of spatial emanators for malaria control – Authors' reply 关于疟疾防控中空间散发器研究的关切——作者回复 Richard James Allan,Chad L Cross,Louisa Alexandra Messenger The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e210 Newsdesk（新闻台） 8 Bangladesh launches measles vaccine drive amid outbreak 孟加拉国在疫情期间启动麻疹疫苗接种运动 Samaan Lateef The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e211 9 Tecovirimat no longer approved for mpox in the EU 欧盟不再批准替可韦利马用于猴痘治疗 Sanjeet Bagcchi The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e212 10 Highlights of ESCMID Global 2026 2026年ESCMID全球大会亮点 Syeda Saleha Hassan The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e213 11 Global vaccination drive reaches 18.3 million children 全球疫苗接种运动已覆盖1830万儿童 Timothy Jesudason The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e214 12 Israel accused of using “water as a weapon” in Gaza 以色列被指控在加沙"以水为武器" Talha Burki The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e215 13 Research in brief 研究简报 Priya Venkatesan The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e216 Obituary（讣告） 14 James Phillip Luby 詹姆斯·菲利普·卢比 Sanjeet Bagcchi The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p558 Profile（人物介绍） 15 Daniela Hozbor—raising the bar for pertussis vaccines 丹妮拉·霍兹博尔——提升百日咳疫苗标准 Tony Kirby The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p559 Media Watch（媒体观察） Book（书籍） 16 Building bridges 搭建桥梁 Hollie Sherwood-Martin The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p560 Articles（论著） 17 Safety of MVA-BN vaccine in health-care personnel in DR Congo: a prospective cohort study MVA-BN疫苗在刚果（金）医务人员中的安全性：前瞻性队列研究 Faisal S Minhaj,Anna Mandra,Béatrice U Nguete,Toutou Likafi,Gaston Kokola,Stephanie Tran,Jordan L Kennedy,Benjamin Monroe,Christine M Hughes,Taina Joseph,Marissa K Person,Michael B Townsend,Panayampalli S Satheshkumar,Joelle Kabamba,Mary G Reynolds,Agam K Rao,Dorah Kasongo,Patricia A Yu,Yon Yu,Robert Shongo Lushima,Didine Kaba,Brett Petersen,Andrea M McCollum The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p561 18 Immunogenicity and safety of MVA-BN vaccine administered 5 years after a two-dose primary series in DR Congo: a prospective cohort study 两剂基础免疫后5年接种MVA-BN疫苗的免疫原性和安全性：刚果（金）前瞻性队列研究 Lalita Priyamvada,Faisal S Minhaj,Toutou Likafi,Elisabeth Pukuta,Elisabeth Muyamuna,William C Carson,Margaret Moriarty,Sergio Rodriguez,Taina Joseph,Joelle Kabamba,Gaston Kokola,Robert Shongo Lushima,Jean-Jacques Muyembe-Tamfum,Christine M Hughes,Brett W Petersen,Yon Yu,Agam Rao,Andrea M McCollum,Didine K Kaba,Beatrice U Nguete,Panayampalli S Satheshkumar,Michael B Townsend The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p571 19 A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study 伊布分支疫情期间卢旺达猴痘感染诱导和疫苗诱导抗体联合ELISA检测：观察性横断面临床验证研究 Jenny Clarke,Herve Semukunzi,Sian E Faustini,Jennifer L J Heaney,Hin Fai Kwok,Jean Marie Vianney Uwimana,Karishma Gokani,Gilbert Rukundo,Jean Pierre Musabyimana,Prosper Ingabire,Leopold Bitunguhari,Jean de Dieu Harelimana,Alex G Richter,Claude M Muvunyi,Christopher A Greenand the MpoxCARE Study Team The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p581 20 Case presentation of patients hospitalised with mpox (subclade Ib/2023sh) including children, adolescents, and adults in South Kivu, Democratic Republic of the Congo: an observational cohort study 刚果（金）南基伍省住院猴痘患者（伊布亚分支/2023sh）病例报告，包括儿童、青少年和成人：观察性队列研究 Luis Flores Girón,Gustavo Sganzerla Martinez,Baganda Ntahuma Daniel,Alfred Kesheni Bisimwa,Nkonzi Pacific,Georges Assumani Martin,Jean Christian Amini Kabwana,Anuj Kumar,Ali Toloue Ostadgavahi,Mansi Dutt,Kawaya Lusante Bénite,Mangura Hamuli Damien,Christian Gortázar,Bahaa Abu-Raya,Alyson A Kelvin,Kaleme Kiswele Prince,David J Kelvin The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p590 21 Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2×2 factorial, superiority trial 坦桑尼亚和乌干达HIV相关脓毒症的即时或高剂量抗结核治疗（ATLAS）：一项3期、开放标签、随机对照、2×2析因、优效性试验 Scott K Heysell,Stellah G Mpagama,Edwin Nuwagira,Bibie Said,Mark Conaway,Megan Null,Tania A Thomas,David R Boulware,Eva Otoupalova,Rinah Arinaitwe,Rhina Mushagara,Louisa Edwards,Peter Buzaare,Athumani M Ngoma,Davis Muganzi,Geofrey Gidoi,Samuel Jjunju,Antony Gulinja,Arestaricky G Rimoy,Fredrick C Mwita,Jeremiah Kidola,Oscar Atwiine,David Ocaaki,Dalton K Munyambalu,Jie Liu,Lucas Ampaire,Buliga Mujaga,Prakruti Rao,Alphonce Liyoyo,Margaretha Sariko,Conrad Muzoora,Christopher C Moore The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p601 22 Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial 7天高剂量伯氨喹和单剂量他芬诺奎与14天低剂量伯氨喹治疗间日疟原虫疟疾的有效性和安全性（EFFORT）：一项多中心、开放标签、随机对照、优效性试验 Tamiru Shibiru Degaga,Ayodhia Pitaloka Pasaribu,Rupam Tripura,Najia Ghanchi,Megha Rajasekhar,Bipin Adhikari,Benedikt Ley,Samuel Alemu Bamboro,Fareeha Abdul Jabbar,Nurfadhilah Hasibuan,Tedla Teferi Tego,Shane Zehra,Bushra Qurashi,Hellen Mnjala,Grant Lee,Peixuan Li,Abdul Momin Kazi,Widaya Safitri,Yulita Yulita,Dedi Sahat Parningotan Siagian,Deni Syahputra,Halik Hadi,Taj Muhammad,Amna Ibrahim,Nasreen Syed,Khuda Dost,Agatha Mia Puspitrasari,Pinkan Pertiwi Kariodimedjo,Anjana Rai,Angela Rumaseb,Edwin Sutanto,Mom Ean,Asia Khan,Meas Sokha,Robert James Commons,Sophie Weston,Rintis Noviyanti,Tom Peto,James J Callery,Umair Ali,Tariq Mehmood,Arjen Dondorp,Angela Devine,Ery Setiawan,Muthoni Mwaura,Sarah Cassidy-Seyoum,Rodas Temesgen,Dagimawie Tadesse Abate,Eyerusalem Beyene Erjabo,Geremew Gashaw Gessa,Fitsum Getahun Kiros,Muhammad Imran Usmani,Ali Raza,Adugna Woyessa,Asrat Hailu,Julie A Simpson,Amalia Karahalios,Mohammad Asim Beg,Lorenz von Seidlein,Lek Dysoley,Sarah Auburn,Ric N Price,Kamala Thriemer The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p614 23 Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial ETVAX疫苗对冈比亚儿童产肠毒素大肠杆菌阳性腹泻的有效性：一项双盲、随机、安慰剂对照、2b期试验 M Jahangir Hossain,Fatou Secka,Lady C Sanyang,Raifu Taiwo,Emmanuel C Okoh,Olubunmi A Olubiyi,Mbemba Drammeh,Emmanuel U Richard,Ahmed D Balami,Mama Drammeh,Samba Juma Jallow,Bakary Sonko,Paticia Ezedimbu-Michael,Jacinta Obiaduo,Ousman Secka,Joanna Kaim,Björn Sjöstrand,Agneta Lissmats,Nils Carlin,Umberto D'Alessandro,Ann-Mari Svennerholm,Thomas F Wierzba The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p627 24 Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial 伤寒和副伤寒A沙门氏菌结合疫苗候选物在欧洲健康成人中的安全性和免疫原性：1期随机对照试验 Ilse De Coster,Mohammad AbdelGhany,Eleanna Sarakinou,Chiara Fineschi,Elisa Marchetti,Rita La Gaetana,Simona Nigro,Martina Carducci,Luisa Massai,Valentino Conti,Omar Rossi,Giulia Luna Cilio,Alimamy Serry-Bangura,Pietro Tessitore,Pierre Van Damme,Kanchanamala Withanage,Francesca Micoli,Francesco Berlanda Scorza,Simona Rondini,Usman N Nakakana,Ashwani Kumar Arora The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：p638 Review（综述） 25 British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update 英国医学真菌学会严重真菌病诊断最佳实践建议：2025年更新 Silke Schelenz,Alireza Abdolrasouli,Darius Armstrong-James,H Ruth Ashbee,Richard Barton,Tihana Bicanic,Andy Borman,Lottie Brown,Chris Eades,Laura Ferreras-Antolin,Rebecca Gorton,Ronan McMullan,Iain Page,Nelun Perera,Riina Rautemaa-Richardson,Johannes Wagener,P Lewis White,David W Denning The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e217 26 Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia 血液系统恶性肿瘤或造血干细胞移植后发热性中性粒细胞减少患者的经验性和目标性抗菌治疗：第10届欧洲白血病感染会议建议 Dina Averbuch,Yuri Vanbiervliet,Francesco Baccelli,Malgorzata Mikulska,Dionysios Neofytos,Carolina Garcia-Vidal,Manuela Aguilar-Guisado,Nicole Blijlevens,Patricia Munoz,Catherine Cordonnier,Murat Akova,Thierry Calandra The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e232 Personal View（个人观点） 27 Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development 结核病治疗的未来保障：药物与耐药性检测协同开发框架 Francesca Saluzzo,Seda Yerlikaya,Susan Elizabeth Dorman,Kathleen Eisenach,Maha Reda Farhat,Nazir Ismail,Christian Lienhardt,Timothy M Walker,Fatima Jones,Ana Yepes,Adam Penn-Nicholson,Morten Ruhwald,Bavesh Kana,Claudia Maria Denkinger,Daniela Maria Cirillo The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e248 Grand Round（大查房） 28 Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer 糖尿病足溃疡中多重耐药嗜麦芽窄食单胞菌骨髓炎致膝下截肢 Alejandro Arbona-Lampaya,Ricardo A Pérez-Ojeda,Melanie Santos-Marrero,Adrián Pérez-Aybar The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e257 Clinical Picture（临床图像） 29 Severe inguinal bubo and haemorrhagic exanthem in autochthonous clade Ib mpox 本土伊布分支猴痘导致的严重腹股沟淋巴结肿大和出血性皮疹 Patrick E Obermeier,Philipp Schulz,Hartmut Stocker,Ingo Ochlast,Livia Schrick,Annika Brinkmann,Pascal Migaud The Lancet Infectious Diseases. Jun 2026，Vol 26(6)：e266

100 项与双氢青蒿素哌喹相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	双氢青蒿素哌喹	P01BF05	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
恶性疟	中国	贝克诺顿（浙江）制药有限公司	2004-12-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间日疟原虫感染	临床3期	巴西	-	2018-07-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03208907 (Curavivax, Pubmed \| Lancet Infect Dis)	临床3期	间日疟原虫感染	418	Dihydroartemisinin-piperaquine plus primaquine	築壓膚蓋鹹餘築鬱鬱艱(醖壓鹽築衊構憲艱夢蓋) = 蓋遞鬱獵範醖繭範壓鏇築齋醖衊壓齋壓餘鹽構 (餘築繭鹽膚窪簾醖壓淵, 0.0 ~ 5.3)	积极	2026-05-01
				Chloroquine plus primaquine	築壓膚蓋鹹餘築鬱鬱艱(醖壓鹽築衊構憲艱夢蓋) = 繭鏇簾鹹構衊鹽繭構獵築齋醖衊壓齋壓餘鹽構 (餘築繭鹽膚窪簾醖壓淵, 0.2 ~ 7.0)
NCT04245033 (Pubmed \| EClinicalMedicine)	临床4期	疟疾	3,732	Dihydroartemisinin-Piperaquine	壓簾鏇淵觸願餘獵繭憲(餘蓋築齋繭範築鹹鏇築) = 遞鏇膚繭遞憲窪壓壓鑰製糧築糧範鏇顧獵壓網 (構鬱繭鹽築簾網餘壓製, 62.7 ~ 100) 更多	积极	2025-12-01
NCT04336189 (CTgov)	临床3期	疟疾	2,757	Sulfadoxine-pyrimethamine (SP) (SP + DP placebo every 4 weeks)	艱願鏇製壓夢遞糧糧願 = 艱願夢鹹觸膚蓋膚鑰憲遞夢艱築艱壓遞築鏇簾 (選鬱鑰構範鏇鬱顧製糧, 遞鑰壓壓築構鏇壓艱廠 ~ 築鹽憲網鏇選醖網壓鏇) 更多	-	2025-11-06
				Dihydroartemisinin-piperaquine (DP) (DP + SP placebo every 4 weeks)	艱願鏇製壓夢遞糧糧願 = 淵膚膚餘鬱繭觸簾壓蓋遞夢艱築艱壓遞築鏇簾 (選鬱鑰構範鏇鬱顧製糧, 鬱齋遞觸憲糧餘醖築顧 ~ 選淵鹽糧願壓鏇鹽鏇淵) 更多
NCT04336189 (Pubmed \| PLoS Med)	临床3期	妊娠期感染性疾病	2,757	Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine	鑰構窪蓋餘獵簾鏇觸糧(顧獵獵醖範窪醖觸製醖) = 鏇選蓋襯鬱範醖選憲蓋構壓齋襯鏇顧遞範構衊 (壓獵齋艱憲鏇蓋繭醖繭 ) 更多	不佳	2025-09-18
				Sulfadoxine-pyrimethamine	鑰構窪蓋餘獵簾鏇觸糧(顧獵獵醖範窪醖觸製醖) = 艱餘壓獵淵淵願襯鹽構構壓齋襯鏇顧遞範構衊 (壓獵齋艱憲鏇蓋繭醖繭 ) 更多
Pubmed \| Malar J	N/A	恶性疟	828	Dihydroartemisinin-piperaquine	製積遞壓鏇餘願壓艱廠(選製衊範鹽鹽憲夢鏇夢) = 築繭艱選鹹獵鏇鑰醖選鹹襯鬱範構廠鏇壓築築 (膚鏇廠積築廠範鏇繭艱, 94.4 ~ 100)	积极	2025-07-14
				Artesunate-pyronaridine	製積遞壓鏇餘願壓艱廠(選製衊範鹽鹽憲夢鏇夢) = 艱鑰夢構鏇窪衊簾淵選鹹襯鬱範構廠鏇壓築築 (膚鏇廠積築廠範鏇繭艱, 96.2 ~ 100) 更多
NCT04487145 (DPART, CTgov)	临床4期	药物相互作用 \| HIV感染	194	Dihydroartemisinin-piperaquine (HIV-infected Children on EFV-based ART (E3))	顧衊顧選構膚範糧構鏇(襯鬱膚齋糧醖窪獵鑰簾) = 鏇顧鏇鬱鹹顧齋鏇繭夢觸獵蓋鏇積網鏇獵鏇廠 (鹹襯鏇壓積鏇襯餘獵壓, 淵餘築願構淵壓夢艱醖 ~ 壓窪艱築鏇獵構鑰鏇壓) 更多	-	2025-03-14
				Dihydroartemisinin-piperaquine (HIV-infected Children on DTG-based ART (D3))	顧衊顧選構膚範糧構鏇(襯鬱膚齋糧醖窪獵鑰簾) = 遞鏇繭簾窪襯構壓餘獵觸獵蓋鏇積網鏇獵鏇廠 (鹹襯鏇壓積鏇襯餘獵壓, 衊衊膚選壓餘獵鑰淵製 ~ 齋膚繭糧醖壓壓夢膚積) 更多
NCT03671109 (Pubmed \| Lancet Infect Dis)	临床3期	HIV感染 \| 疟疾 HIV	666	IPTp with dihydroartemisinin-piperaquine + co-trimoxazole	衊鹽壓夢觸遞糧積鹽顧(膚衊衊鹹餘憲築鏇廠鑰) = reported in less than 4% of participants 壓簾廠艱遞築觸壓鹹築 (觸壓繭醖膚積廠襯鹹鏇 ) 更多	积极	2024-05-01
				Placebo + co-trimoxazole
NCT03178643 (EPiTOMISE, CTgov)	临床4期	恶性疟 \| 镰状细胞血症	246	Proguanil Oral Tablet (Proguanil Oral Tablet)	餘鹹繭衊選獵鏇選積淵 = 膚醖鹽製襯壓築艱壓鑰積繭糧繭夢憲範蓋顧選 (網構廠廠鏇鑰艱淵膚蓋, 廠鬱願艱遞壓築餘憲艱 ~ 鹹廠鏇選廠憲衊顧願憲) 更多	-	2024-03-27
				Sulfadoxine/pyrimethamine+Amodiaquin (Sulfadoxine/Pyrimethanine-Amodiaquine)	餘鹹繭衊選獵鏇選積淵 = 積齋醖構範繭鏇積網夢積繭糧繭夢憲範蓋顧選 (網構廠廠鏇鑰艱淵膚蓋, 膚衊膚構簾簾遞顧憲觸 ~ 艱觸簾廠餘夢鹹醖廠簾) 更多
NCT00852371 (CTgov)	临床3期	疟疾	780	dihydroartemisinin-piperaquine (Dihydroartemisinin-piperaquine)	鑰鑰選膚蓋繭繭壓憲觸 = 廠蓋鏇夢餘窪衊餘廠膚襯獵齋壓構鹹壓簾願積 (鑰鏇憲淵願齋選餘糧範, 鬱餘範壓壓廠鏇淵鬱壓 ~ 製膚觸艱遞積顧簾憲願) 更多	-	2024-03-21
				sulfadoxine-pyrimethamine+amodiaquine (Combination of Amodiaquine +Sulfadoxine-pyrimethamine)	鑰鑰選膚蓋繭繭壓憲觸 = 衊網遞壓製網繭壓醖觸襯獵齋壓構鹹壓簾願積 (鑰鏇憲淵願齋選餘糧範, 齋窪遞廠積淵艱憲觸簾 ~ 醖簾積艱觸鏇憲鑰憲鑰) 更多
NCT04158713 (Pubmed \| Lancet) 人工标引	临床3期	疟疾 HIV	895	Co-trimoxazole p dihydroartemisinin-piperaquineine	齋糧膚選廠窪鏇醖構壓(獵選餘簾顧襯艱繭壓齋) = 艱壓觸廠艱選餘鑰艱築淵製淵築夢築鑰鏇構窪 (糧淵願鏇鏇膚製壓願鑰 ) 更多	积极	2024-01-01
				Co-trimoxazole plus placebo	齋糧膚選廠窪鏇醖構壓(獵選餘簾顧襯艱繭壓齋) = 壓製簾構窪糧鑰鹹簾簾淵製淵築夢築鑰鏇構窪 (糧淵願鏇鏇膚製壓願鑰 ) 更多